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Preface 
With this report, DrugScience provides a unique opportunity for the World Health 
Organization (WHO) and its Expert Committee on Drug Dependence to initiate a critical 
review process of cannabis and cannabis resin for their scheduling under the Single 
Convention on Narcotic Drugs as amended by the 1972 Protocol. The process could 
ultimately open the discussion on the scheduling of cannabis and cannabis resin and lead to 
recommendations to the Commission on Narcotic Drugs within two years. 
 
In the eighty years since cannabis and cannabis resin were last reviewed by the Health 
Committee of the League of Nations in 1935, both the social context of cannabis use and the 
science of drug dependence have dramatically changed. Yet, cannabis and cannabis resin 
continue to remain under the strictest control regime possible under the Single Convention, 
without a valid scientific re-assessment of this decision. Cannabis and cannabis resin are 
listed in Schedule I and Schedule IV respectively, which means that both remain strictly 
prohibited worldwide. 
 
This also means that the Committee implicitly continues to recommend that cannabis 
is not to be used medically despite growing evidence of medical use worldwide and despite 
the availability of pharmaceutical preparations with a marketing authorization in multiple 
countries. Many countries are struggling with the impact of the prohibition of cannabis, be it 
the negative impact of prohibition on society, including over-incarceration and 
disproportionate sentencing, or impact on drug markets (including synthetic cannabinoids) 
and drug use.  
 
The current scheduling of cannabis is in marked divergence with the Convention’s 
principle that scheduling of substances should be based on a scientific assessment by WHO. 
In the absence of a recent assessment, the continued prohibition of cannabis appears 
completely illegitimate even though it may be legal. 
 
A scientific review by the WHO, the only authoritative global body to make such an 
assessment, would greatly legitimize international policies and their national implementation. 
A scientific assessment of cannabis and cannabis resin appears most timely given the many 
debates that have emerged on this issue across the world in recent years. 
 
I trust therefore, that the Thirty-eighth Meeting of the Expert Committee on Drug 
Dependence will act responsibly and will adopt, on the basis of this strong Pre-Review 
Report, the Pre-review of Cannabis and Cannabis Resin as an agenda item. 
 
Geneva, September 2016 
Michel D. Kazatchkine 
Commissioner of The Global Commission on Drug Policy; Professor of medicine; former 
Executive Director of the Global Fund to fight AIDS, tuberculosis and malaria. 
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Foreword 
The WHO Expert Committee on Drug Dependence (ECDD) recommended in its 35th 
(2012), 36th (2014) and 37th (2015) Sessions that a Pre-review of cannabis and cannabis resin 
should be undertaken. However, the ECDD Secretariat, when announcing the 38th Meeting, 
proposed that cannabis will be on the agenda of the 38th Meeting (14 – 18 November 2016) 
only as “Update”.  
 
When the ECDD will meet in November 2016, it will discuss this proposed agenda, 
and then will decide on the final agenda (which is at the liberty of the Expert Committee). 
DrugScience requests the Experts to amend the proposed agenda and replace the agenda item 
“Update of Cannabis” with a “Pre-review of Cannabis”. In this way, the ECDD could decide 
to conduct a Critical Review in its next meeting, which could then lead to scheduling 
recommendations to the Commission on Narcotic Drugs. Such a decision would not be 
possible when the agenda item is an Update. 
 
A Pre-review requires that the ECDD considers the pertinent information on the 
subject. Therefore, for this purpose, DrugScience prepared this Pre-review Report of cannabis 
and cannabis resin (also including their preparations). This Pre-review Report has been 
prepared with the same rigour as if it would have been prepared by the WHO Secretariat. It 
meets the standards as outlined by the Executive Board in its Guidance on the review of 
psychoactive substances for international control. (World Health Organization, 2010) 
 
The report has been written by an independent expert team with a broad knowledge 
and expertise, including the medical and non-medical use of cannabis, assessment of clinical 
evidence, pharmaceutical production methods of cannabis, and legal and administrative 
aspects of drug control. In this respect, their expertise is even broader than usual for ECDD 
review reports.  
 
The scheduling under the Single Convention on Narcotic Drugs assumes a scientific 
justification. However, cannabis and cannabis resin have never been evaluated by WHO since 
it was mandated the review of psychoactive substances in 1948. The last evaluation for the 
international substance control conventions were therefore when the League of Nations 
evaluated them in 1924 and 1935. 
 
The only recommendations by the Expert Committee were repeated recommendations 
in the 1950s and the 1960s calling on countries not to allow medical use of cannabis. These 
recommendations still stand. Not only are they at the basis of the prohibition of medical use in 
many countries but they are also the justification for inclusion of cannabis and cannabis resin 
in Schedule IV of the Convention, which classifies them among the substances with the 
strictest prohibition.  
 
With this report, DrugScience enhances the ability of the World Health Organization 
and its Expert Committee on Drug Dependence in fulfilling its international obligations and 
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enables the Expert Committee to arrive at an independent and scientific recommendation 
whether a Critical Review is warranted or not. 
 
Professor David Nutt, DM, FRCP, FRCPsych, FMedSci 
Chair, 
DrugScience 
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Abbreviations and acronyms 
 
AUC area under the curve 
CBD cannabidiol 
CBN cannabinol 
CB1R  Cannabinoid type-1 receptor or CB1 receptor 
CND Commission on Narcotic Drugs 
CFU colony forming units 
CSF  cerebral spinal fluid 
DSM  Diagnostic and Statistical Manual 
eCB  endocannabinoid 
ECDD Expert Committee on drug Dependence 
EMCDDA European Monitoring Centre on Drugs and Drug Addiction 
GAP Good Agricultural Practices 
GDP Good Distribution Practices 
GLcP Good Laboratory control Practices 
GMP  Good Manufacturing Practices 
IACM International Association for Cannabinoid Medicines 
INCB International Narcotics Control Board 
IQ intelligence quotient 
ISCD Independent Scientific Committee on Drugs 
MS multiple sclerosis 
NNT number needed-to-treat 
MW molecular weight 
PET  positron emission tomography 
RA rheumatoid arthritis 
RCT randomised controlled trial 
THC tetrahydrocannabinol 
UHR  ultra-high risk 
UNODC United nations Office on Drugs and Crime 
WHO World Health Organization 
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Introduction 
A Pre-review for the scheduling of Cannabis and Cannabis resin under the 
international drug control conventions is much needed, as explained in the Foreword by 
Professor David Nutt. This Pre-review Report provides the data for such a Pre-review by the 
WHO Expert Committee on Drug Dependence. 
 
The purpose of a Pre-review is to determine whether current information justifies a 
Critical Review. For evaluating substances in a Pre-review, the categories of information are 
identical to those used in Critical Reviews. At the stage of the Pre-review, the Expert 
Committee must decide whether the information justifies a Critical Review. If it finds that the 
data available may justify changing the scheduling of cannabis and/or cannabis resin, the 
Committee should recommend a Critical Review in its next Meeting. The Pre-review is a 
preliminary analysis, and findings at this stage should not determine whether the control 
status of a substance should be changed. 
 
If the Committee decides that a Critical Review is warranted, there will be a number of 
assessments to be made by the Committee in its next session: 
 
The current control is through Schedules I and IV of the Single Convention on 
Narcotic Drugs as amended by the 1972 Protocol. When reviewing it, cannabis needs to be 
assessed against the criteria for listing a substance in these two Schedules in order to 
determine whether they are still met today. If not, the question is whether cannabis meets the 
criteria for other Schedules, particularly Schedule II of the Single Convention, or does not 
meet the criteria for any scheduling. 
 
The full procedure to arrive at a decision is presented in the Guidance on the WHO 
review of psychoactive substances for international control. (World Health Organization, 
2010) However in short, the pertinent criteria for the Critical Review of cannabis and 
cannabis resin are the following: 
1. The applicability of the Single Convention should be assessed, before considering the 
Psychotropic Substances Convention; if a substance is cannabis-like and the Committee 
decides that it should be scheduled, it should be scheduled under the Single Convention. 
2. The next step is to decide whether a substance is “liable to similar abuse and 
productive of similar ill-effects as the substances already in Schedule I or II”. If this is the 
case, the Committee should recommend scheduling, if not, it should recommend removal 
from all Schedules. 
For substances already scheduled under the Single Convention, Article 3, paragraph 6 
applies and not Article 3, paragraph 3. This makes a difference in so far that substances 
already scheduled can be moved to another schedule or completely removed. Because 
paragraph 3 of the same article is not applicable to substances already scheduled, its 
“similarity-rule” (that requires that the ECDD assesses whether the substance under review 
is cannabis-like) does not apply either. This is supported by the official Commentary to the 
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Convention concerning the scheduling of cannabis and its resin in Schedule IV: “…Should 
the results of the intensive research which is at the time of this writing being undertaken on 
the effect of these two drugs so warrant, they could be deleted from Schedule IV, and these 
two drugs [i.e. cannabis and cannabis resin], as well extracts and tinctures of cannabis, 
could be transferred from Schedule I to Schedule II.” (Anonymous, 1973a) The quote 
shows that there is also no impediment for the Committee to recommend a deletion if it 
should conclude that this is justified. 
3. In the next step, the Committee should decide whether Scheduling should be in 
Schedule I or II. Unfortunately, neither the text of the Convention nor the Guidance 
provide criteria for the choice for Schedule I or Schedule II. However, the official 
commentary to the Single Convention explains that the criteria used by the Technical 
Committee of the Plenipotentiary Conference (i.e. the Conference of the countries that 
negotiated the conventions in the 1950s and 1960s) included that dependence-producing 
properties stronger than codeine and more or less comparable to morphine led to 
Schedule I and dependence-producing properties not greater than those of codeine but at 
least as great as those of dextropropoxyphene led to listing in Schedule II. Although this 
seems to be clear, the full list of criteria used by the Technical Committee is confusing and 
intrinsically contradictory, including a criterion on comparability to cannabis and cannabis 
resin. (Anonymous, 1973)  
4. If the Committee recommends the substance to be scheduled in Schedule I, it should 
also assess whether it is “particularly liable to abuse and to produce ill effects […] and that 
such liability is not offset by substantial therapeutic advantages not possessed by 
substances other than drugs in Schedule IV.” (Anonymous, 2009)  
 
Moreover, there exist recommendations by the Committee from 1955, 1960, 1965 and 
1968 that cannabis and cannabis resin should not be used medically. Because these 
recommendations were never revoked, they still stand. However, since then much progress 
has been made in research, and also the professional cultivation of herbal medicines has been 
standardized in several cases, resulting in reproducible products. Moreover, a cannabis extract 
with the status of a licensed medicine is available in 28 countries. This requires that the 
Committee provides clarity by either repeating or revoking the earlier recommendations on 
this issue.  
 
Finally, an increasing number of countries adopt alternative policies to mitigate the 
harm of cannabis and its prohibition. In many countries legal provisions exist that allow 
people in one way or another to produce and use cannabis without fear of legal prosecution. 
These provisions have many names: legalization, regulation, condoning etcetera. As a 
consequence, many people are exposed to cannabis more or less legally, but the quality is not 
always ensured. This exposes users unnecessarily to hazards from impurities that should and 
could be avoided, such as moulds and fungi (esp. A. fumigatus), heavy metals and pesticides. 
  
The Committee, being a panel with specific pharmaceutical expertise, should make 
recommendations to those jurisdictions allowing the production and use of cannabis to 
establish quality assurance systems. As the latter two issues are somewhat separate from the 
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recommendations on scheduling, the Committee can, if it prefers to do so, make 
recommendations on medical use and quality control already during its current session. 
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1. Substance identification  
A. International Nonproprietary Name (INN) and other generic designations 
There is no INN for Cannabis sativa L.  
 
The main active constituent of cannabis is dronabinol INN. Dronabinol is often also 
called Δ9-tetrahydrocannabinol, or tetrahydrocannabinol (THC), In this document, 
dronabinol, Δ9-tetrahydrocannabinol, tetrahydrocannabinol and THC are used as 
synonyms. 
 
Cannabinol (another natural cannabinoid) has been assigned an INN as well. 
 
No other constituents are assigned an INN.  
 
Moreover, a standardized cannabis extract containing Δ9-THC and cannabidiol has 
been denominated nabiximols USAN. The USAN system is coordinated with the INN system 
and therefore a future identical INN designation for this extract may be possible. 
B. Botanical classification 
Order: Rosales 
Family: Cannabaceae 
Genus: Cannabis L. 
Species Cannabis sativa L. 
C. Chemical Abstract Service (CAS) Registry Number 
Not applicable 
D. Proprietary names 
Bedrocan
®
, Bedrobinol
®
, Bediol
®
, Bedica
®
, Bedropuur
®
 and Bedrolite
®
 
are varieties of commercially available pharmaceutical grade herbal cannabis  
Sativex
® 
is a standardized extract of cannabis (nabiximols USAN) 
(Marinol
®
 is dronabinol INN) 
E. Colloquial names 
There are more than 100 street names in English and dozens in virtually every other 
major language. In English they include cannabis, marijuana, skunk, herb, resin, weed, ganja, 
purple haze, northern lights, charis, Thai sticks, grass, pot. 
F. WHO Review history
1
 
Cannabis and Cannabis Resin are scheduled in Schedules I and IV of the Single 
Convention on Narcotic Drugs since the Convention has been agreed. (Anonymous, s.a.) 
                                               
1 This section is based on a document prepared by the author for the 36th Meeting of the Expert 
Committee on Drug Dependence. 
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These substances were discussed internationally for the first time at the The Hague 
Conference of 1912, (International Narcotics Control Board, 1978) but it was only the second 
Opium Convention of 1925 that regulated the international trade of “Indian hemp”, its resin 
and its galenic preparations. It allowed for the medical and scientific use of galenic 
preparations. (International Narcotics Control Board, 1978; Danenberg et al., 2013) 
 
Cannabis was reviewed by the Health Committee of the League of Nations in 1935, 
which recommended that preparations obtained from cannabis extract or tincture were placed 
under control of the second Opium Convention. (International Narcotics Control Board, 1978; 
Danenberg et al., 2013) 
 
After World War II, WHO became responsible for the health functions of the League 
of Nations. The Expert Committee on Drugs Liable to Produce Addiction, later called the 
Expert Committee on Addiction-Producing Drugs (and today called the ECDD) spoke out 
against the medical use of cannabis repeatedly (e.g. fifth (1955), 11th (1960), 14th (1965) and 
16th  Sessions (1968)). (World Health Organization, 1955; World Health Organization, 1960; 
World Health Organization, 1965; World Health Organization, 1968) However, in none of 
these cases there was a review of the dependence-producing properties of the substance. A 
document by the International Narcotics Control Board (INCB) mentions that WHO produced 
a report on the physical and mental effects of cannabis in 1953, but this document was lost 
over time. It is not clear whether the Expert Committee on Drugs Liable to Produce Addiction 
was involved with it. (International Narcotics Control Board, 1978; Wolff PO, 1955)  
 
Because of their inclusion in the 1925 Opium Convention, cannabis and cannabis resin 
were later included in Schedule I of the Single Convention on Narcotic Drugs, when this 
convention replaced an earlier drug control convention in 1961. When the Schedules of the 
Single Convention were drawn up, the Expert Committee on Addiction-Producing Drugs 
stated that it “believed that the composition of the schedules (on the draft list for the Single 
Convention) should be most carefully reviewed before they become an established part of the 
new Convention”. (World Health Organization, 1959) Yet, the Expert Committee’s tenth 
report only mentions that substances in Schedule III were reviewed individually, whilst the 
review of other Schedules seem to have been a quick check of the lists with a few remarks to 
move substances to other Schedules. No reference is made to a review of cannabis and/or its 
resin. (Danenberg E et al., 2013;  World Health Organization, 1960) The Expert Committee’s 
13th report also mentions a review of substances for the Single Convention without a specific 
reference to a review of cannabis or cannabis resin. (World Health Organization, 1964) 
 
The Technical Committee of the Plenipotentiary Conference, which was the 
conference of the countries where the Single Convention was negotiated, included both 
substances also in Schedule IV. The Technical Committee used the following criteria for 
inclusion: Substances “(a) Having strong addiction-producing properties or a liability to abuse 
not offset by therapeutic advantages which cannot be afforded by some other drug; and/or (b) 
For which the deletion from general medical practice is desirable because of the risk to public 
health”. (Anonymous, 1973c) 
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Of interest is also that the 35th Expert Committee on Drug Dependence conducted a 
Critical Review of dronabinol in 2006 and recommended to move the substance from 
Schedule II of the United Nation Convention on Psychoactive Substances to Schedule III. 
(World Health Organization, 2006a; World Health Organization, 2006b) This was rejected 
then by the Commission on Narcotic Drugs without making mention of what the required 
social or economic considerations for such a rejection were. (Commission on Narcotic Drugs, 
2007) Although dronabinol is regulated as a separate identity under the drug control 
conventions, this is important because it is also the main constituent of cannabis and cannabis 
resin. 
 
In 2009, the Commission on Narcotics Drugs (CND) requested in its Resolution 52/5 
“Exploration of all aspects related to the use of cannabis seeds for illicit purposes”, “the 
United Nations Office on Drugs and Crime to share information regarding the health risks 
posed by cannabis with the Expert Committee on Drug Dependence of the World Health 
Organization, and, in that regard, looks forward to an updated report on cannabis by the 
Expert Committee, subject to the availability of extra budgetary resources”. (Commission on 
Narcotic Drugs, 2009)   
 
From 1968 until 2014, cannabis has never appeared on the agenda of the Expert 
Committee. From 2014 onward, the 35th, 36th and 37th Meetings of the Committee agreed to 
review cannabis in a future meeting of the Committee. (World Health Organization, 2012)  
This has not been substantiated so far and only “intermediate” documents have been 
discussed. (Madras BK, 2015; Anonymous, 2014) 
 
In 2016, WHO published the report “The health and social effects of nonmedical 
cannabis use”. (World Health Organization, 2016) However, although useful, this report was 
not prepared for conducting a review by the Committee and does not cover all the required 
topics or meet the required format.  
2. Botany and chemistry  
A. Description of the plant 
UNODC describes the physical appearance as ‘Cannabis is an annual, dioecious, 
flowering herb. Staminate (male) plants are usually taller but less robust than pistillate 
(female) plants. Stems are erect and can vary from 0.2-6 m. However, most of the plants reach 
heights of 1-3 m. The extent of branching, like the plant height, depends on environmental 
and hereditary factors as well as the method of cultivation’. (United Nations Office on Drugs 
and Crime, 2009) An image of a male and a female plant are shown in Figure 1. 
B. Plant varieties 
Often two varieties are distinguished: Cannabis sativa L. spp. sativa and Cannabis 
sativa L. spp. indica. There are morphological and chemical differences between these two. 
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Within the subspecies, there are numerous varieties.  Some distinguish a third subspecies: 
Cannabis sativa L. spp. ruderalis. 
 
Figure 1. A flowering 
male and seed-bearing female 
plant. 1. male flower, enlarged 
detail; 2. and 3. pollen sac of 
same from various angles; 4. 
pollen grain of same; 5. female 
flower with cover petal; 6. female 
flower, cover petal removed; 7. 
female fruit cluster, longitudinal 
section; 8. fruit with cover petal; 
9. same without cover petal; 10. 
same; 11. same in cross-section; 
12. same in longitudinal section; 
13. seed without hull. (Köhler 
FE. Köhler’s Medizinal-Pflanzen 
in naturgetreuen Abbildungen 
und kurz erläuterndem Texte. 
1887) 
 
 
 
 
C. Treaty definitions  
Cannabis is defined in the Single Convention on Narcotic Drugs as “the flowering or 
fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by 
the tops) from which the resin has not been extracted, by whatever name they may be 
designated.”  
 
Cannabis resin is defined as “separated resin, whether crude or purified, obtained from 
the cannabis plant.”  
 
It should be noted that what the Conventions consider to be cannabis and cannabis 
resin does not refer to the whole plant. Thus, treaty definitions are narrower than the botanical 
definition. Other parts of the plant are not under international control.  
D. Constituents
2
 
Over 60 cannabinoids have been identified in Cannabis sativa L., but many of these 
are not or only marginally explored for their properties. (Pertwee RG, 2004)  The two main 
                                               
2 This subsection is based on a document prepared by the author for the 36th Meeting of the Expert 
Committee on Drug Dependence. 
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cannabinoids in most varieties are Δ-9-tetrahydrocannabinol  and cannabidiol (CBD). Other 
cannabinoids naturally occurring in the plant include cannabichromene, cannabigerol, 
cannabichromevarin, tetrahydrocannabivarin etcetera. All the cannabinoids are present as 
carboxylic acids and are decomposed on heating into the free cannabinoids. Cannabinol is 
present in dried cannabis, but is a decomposition product. All these cannabinoids differ in 
pharmacodynamical properties: agonists, partial agonists or antagonist, with different 
affinities to the various cannabinoid like receptors, such as CB1, CB2 and the Transient 
Receptor Potential V1 (TRPV1) or vanilloid receptor. The free cannabinoids have different 
activities than the cannabinoid acids. Some cannabinoids may be pharmacologically inactive. 
 
Usually, varieties of Cannabis sativa L. spp. sativa are relatively strong on 
tetrahydrocannabinol, while varieties of Cannabis sativa L. spp. indica are relatively high on 
cannabidiol.  
 
Moreover, plant material contains many substances from various other chemical 
classes, such as terpenes and flavonoids. The typical number of substances that can be 
identified in a plant is 700 – 1000, most of them not psychoactive. However, it should be 
considered that these other constituents may act as uptake enhancers (i.e. bioavailability 
enhancers) for other substances, e.g. this is known to be the case for some terpenes. 
(Kesarwani K and Gupta R, 2013) 
 
Both plant genotype and phenotype can make a difference for the actual composition 
of a cannabis batch. These differences can have consequences for the psychopharmacological 
and other pharmacological activity of the plant. (Scholten WK, 2006) Therefore, there is not 
“one cannabis”: the actual content of tetrahydrocannabinol in the flowering tops can vary 
from very low (under 0.9 % for the approved industrial varieties in the EU, to up to 28 %). 
Moreover, the variety in cannabinoid profiles and the presence of different uptake enhancers 
cause a diversity of properties of the many cannabis varieties.   
E. Chemical formulas of some main constituents 
dronabinol:  C21H30O2 
cannabidiol:  C21H30O2 
cannabinol:  C21H26O2 (Chemspider, website) 
F. Structural formulas of some main constituents 
dronabinol:    cannabidiol:                      cannabinol: 
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G. Molecular weights of some main constituents 
Molecular weight (M.W.) of dronabinol:    314.46 gram/Mol 
M.W. of cannabidiol:     314.46 gram/Mol 
M.W. of cannabinol:      310.43 gram/Mol 
H. Melting points of some main constituents 
dronabinol:  200   °C 
cannabidiol:   66    °C 
cannabinol:  76.5  °C 
I. Cultivation 
The illicit cultivation of cannabis has been comprehensively described by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which has been 
used to draft the subsections on outdoor and indoor cultivation. We refer for more details to 
its report on this topic.(European Monitoring Centre for Drugs and Drug Addiction, 2012a) 
Open air cultivation 
Originating from Central Asia, the cannabis plant had already spread around the world 
in ancient times. It served for the production of fibres (hemp for ropes and cloth), the 
extraction of oil from the seeds (for culinary purposes and as lamp oil) and for its 
psychoactive properties. Nowadays, there is open air cultivation almost around the world, as 
the plant will grow up to a latitude of 55°N.  
 
For the cultivation of the fibres, both the male and female plants are cultivated. The 
plants are sowed in spring (late April or May) and the harvest takes place relatively early. The 
stems of the plants, usually 2 -3 meters high and even higher at times, are put in water in 
order to make them rot. After this “retting”, the fibres can be set free by crushing the stems. 
 
For the production of drug, the goal is to obtain the flowers. Because the plant starts 
flowering only when the days start shortening, the harvest is much later in the season than for 
fibre hemp, usually at the beginning of October. In countries closer to the equator however, 
varieties are adapted to the more constant day length and start flowering when sufficiently 
mature. 
 
If  the plant is cultivated by sowing, there will be male and female plants and the 
flowers will contain seeds at the moment of harvesting. Another option is to clone female 
plants selectively. This will result in seedless flowers (“sensimilla”), which have usually a 
higher content of tetrahydrocannabinol. 
 
In southern and eastern Europe, in Asia and in Africa, the prevailing method of hemp 
cultivation is outdoor, while in most western and northern European countries there is a 
preference for indoor cultivation. In more northern countries, bad weather conditions can ruin 
the crop because the flowers will rot before they are fully grown. 
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To harvest the herbal cannabis (or “marijuana”, as the product is called in the USA),  
the flowers and upper leaves are cut from the plant and allowed to dry,  then compressed into 
dense blocks to minimize the volume for transportation. 
 
Cannabis resin is prepared by trashing and sieving the sun-dried flowers. In this way 
the gland cells containing the essential oil with the cannabinoids are separated. They are 
compressed, resulting in a dark-brown resin. Because of differences in processing, resin 
originating from various countries can be very different. 
Indoor cultivation 
In case of illicit production, indoor production has the advantage that it can be hidden 
more easily, although premises with indoor production can be detected with Infra-Red (air) 
photography and by identifying buildings with high electricity consumption.  
 
Through indoor cultivation, the environment can be better controlled, and hence, the 
product properties too, especially if not grown in glass-houses but in sealed rooms. 
Temperature, lighting (including day length), humidity, watering and fertilization can be 
controlled to a very high level. This is at a higher cost, mainly because of the electricity 
needed for the powerful lamps in use (typically 400 – 600 W/m2); however, the electricity is 
often stolen so the costs are not a concern for the illicit grower. By indoor cultivation it is 
possible to reach six to eight harvests per year.  
 
Usually plants are grown in individual pots with soil, sometimes hydroponically. Once 
the plants are ready for harvesting, they are cut and hung to dry. After about two weeks, the 
flowering tops are cut off the plant and the leaves and stems are cut out by hand with scissors 
(“manicured”). 
 
Sometimes the waste from the manicuring and the leaves is used to separate and 
collect the glandular hairs using ice water and sieves. This result in a product called “modern 
hashish”, which has potentially a high content of THC. 
 
The main determinant for the yield is the strain, followed by the amount of lighting. 
Cultivation for pharmaceutical purposes 
For the cultivation of cannabis for pharmaceutical purposes, the same techniques can 
be used as described above. Some production of medical cannabis is illegal, and in some 
states in the USA the production of medical cannabis is in the hands of individuals, cannabis 
clubs, or (semi-) professional organizations with no supervision on the quality by the health 
authorities. On the other hand, legal producers apply very professional techniques in order to 
arrive at a product that meets all pharmaceutical requirements. Therefore, we may assume that 
all sorts of cultivation exists, from bad to excellent. 
 
38th ECDD (2016)                                  Pre-review Report Cannabis and Cannabis resin 
 
 19 
In some countries, including Canada, the United Kingdom and the Netherlands, the 
marketed product meets pharmaceutical standards. In the United Kingdom, where the 
production is intended to produce a standardized extract (Sativex
®
), the cultivation is partially 
standardized and after extraction, the concentration of the cannabinoids is adjusted until to the 
required level. In the Netherlands, where the inflorescence is prescribed to the patient, the 
cultivation is standardized to a high level, in order to have batch-to-batch consistency . 
Various products are available, and therefore the variety needs specification. 
3. Ease of convertibility into controlled substances 
The criterion for ease of convertibility has been set by the World Health Assembly in 
its Resolution 7.7 of 1954. A substance will be considered by the World Health Organization 
as "convertible" where the ease of conversion and the yield obtained constitute a risk to public 
health, and that in cases where there is uncertainty as to whether a substance will fall under 
this definition, the substance will be considered as "convertible" rather than as "not 
convertible". The Guidance on the WHO review of psychoactive substances for international 
control defines Ease of convertibility in its paragraph 49 as “A substance is convertible if it is 
of such kind as to make it, by the ease of the process and by the yield, practicable and 
profitable for a clandestine manufacturer to transform the substance in question into 
controlled drugs”. (World Health Organization, 1954)  
 
Related controlled substances which are candidate for being converted from cannabis 
are dronabinol (controlled under Schedule II of the Convention on Psychotropic Substances) 
and six stereoisomers of this substance (the 7,8,9,10-; 8,9,10,10a-; 6a, 9,10,10a-; 6a,7,10,10a- 
6a,7,8,9-;  and 6a,7,8,9,10,10a- configurations of tetrahydro-6,6,9-trimethyl-3-pentyl-6H-
dibenzo[b,d]pyran-1-ol). The latter are controlled under Schedule I of the same convention. 
 
 Cannabidiol and cannabidiolic acid can be extracted from fibrous hemp or from low 
THC containing hemp seeds using solvents and is then purified to a crystalline substance. 
(Cannabidiol Solutions, website)  Cannabidiol obtained by decarboxylation is cyclized in the 
presence of Lewis acids in a non-polar solvent to produce dronabinol. 
 
The fact that dronabinol and the other scheduled stereoisomers are never encountered 
in drug markets show that conversion is not an issue. Instead, similar products such as 
“cannabis oil” with high dronabinol content but lower purity are made in much simpler ways 
directly from cannabis or cannabis resin.   
4. General pharmacology, including pharmacokinetics and 
pharmacodynamics  
Pharmacodynamics 
Most of the actions of cannabinoids are mediated by actions at two G-protein coupled 
receptors, named CB1 and CB2 receptors. In addition, there is evidence for non-receptor 
38th ECDD (2016)                                  Pre-review Report Cannabis and Cannabis resin 
 
 20 
dependent mechanisms of cannabinoids. The effects of cannabinoids can be blocked by 
selective receptor antagonists such as rimonabant. (Nutt DJ, 2005) 
 
The CB1 cannabinoid receptors are distributed in the central nervous system where 
they are the most dense of all G-protein coupled receptors (their total number exceeding that 
of dopamine, noradrenaline and serotonin receptors put together). CB2 receptors are found in 
many peripheral tissues (spleen, leukocytes; reproductive, urinary and gastrointestinal tracts; 
endocrine glands, arteries and heart, etc.). 
 
The brain makes several substances (called endogenous cannabinoids or 
endocannabinoids) such as anandamide and diacylglycerol that are agonists at cannabinoid 
receptors  where they produce alterations in synaptic connectivity. The endocannabinoids are 
produced by breakdown of phospholipids in cell membranes during and after neuronal 
activity. Cannabis mimics the effects of the endogenous neurotransmitters anandamide and 
diacylglycerol. (Devane WA et al., 1992; Di Marzo V et al., 2001; Mechoulam R, Fride E and 
Di Marzo V, 1998; Segiura T et al., 1997) 
 
Cannabinoids of herbal origin, particularly THC, mimic to a greater or lesser extent 
the effects of these endocannabinoids. (Grotenhermen, 2004) Not all naturally occurring 
cannabinoids exhibit the same pharmacological activity. They can have higher affinity to the 
CB1, to the CB2 or to the vanilloid receptor (TRPV1), and they can be agonists, antagonists or 
partial agonist. (Pertwee RG, 2004) 
 
Cannabis may inhibit endorphins in the emetic centre, suppress prostaglandin 
synthesis, and/or inhibit medullary activity through an unspecified cortical action. (Drug 
Bank, website) 
 
CB-receptors are over 600 million years old. They are present all over the animal 
kingdom, even in the very primitive Hydra vulgaris (Pallas). CB receptors are much older 
than the cannabis plant, which dates back to the Oligocene (34 million years ago).
1
 
(McPartland JM and Guy GW, 2004)  This is an indication that the endocannabinoid system 
has its own physiological function and that its origins are not related with the use of the 
cannabis plant. This physiological function exists inter alia in the modulation of  pain 
experience and appetite. 
 
The brain effects of THC are mediated via agonist activity at CB1 receptors, which are 
found at high concentrations in brain areas associated with motivation and reward. THC has 
been shown to increase the release of dopamine from the nucleus accumbens and prefrontal 
cortex in rodents, an effect found with many substances of misuse. (Tanda G, Pontieri FE and 
Di Chiara G, 1997) However the human data are unconvincing. (Nutt et al., 2015) 
 
THC is the main cause of the pharmacological effects of cannabis, including the 
medicinal benefits of the plant. It is an agonist to both the CB1 and the CB2 subtype of these 
receptors. It is thought that the anti-emetic effects are also partly mediated by the CB1 
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receptor. THC also acts on CB2 receptors and this action on those found in the immune 
system may explain its actions in inflammatory conditions. 
 
 Cannabidiol, which has two isomers, is another cannabinoid that has actions that in 
some ways oppose those of THC through as yet-to-be-understood mechanisms. The relative 
lack of cannabidiol in some forms of plant cannabis (e.g. skunk) may help explain different 
effects of these compared with the more balanced mixtures of THC and cannabis found in 
more traditional varieties. (See also Section 7. Dependence potential, Subsection “Cannabis 
and psychosis”)  
 
Cannabinol is not naturally occurring in the living cannabis plant, but it occurs usually 
in the dried herb as a degradation product of THC. Δ8-THC is another cannabinoid, which is 
present in the plant in small amounts. 
 
Table 1. Effects of  cannabinoids on various receptors. (Pertwee RG, 2004) 
effect on:  CB1-receptor CB2-receptor TRPV1 
THC ++ + 0 
Δ8-THC + + 0 
(+)-cannabidiol +/- + + 
(-)-cannabidiol 0 0 + 
cannabinol +/- + 0 
+ = agonist; +/- = partial antagonist; 0 = no effect 
Pharmacokinetics of inhaled cannabis 
Measuring the kinetics of cannabis reliably is not easy when it comes to smoking of 
cannabis cigarettes. Combustion takes place at 700 – 850° C and around 30 %  of the 
cannabinoids is destroyed by pyrolysis during smoking. Bioavailability of smoking is reported 
as ranging from 2 – 56 %. (Grotenhermen F, 2003) By using a vaporizer device, the intake is 
more reliable and contrary to smoking, vaporizing is not associated with the inhalation of 
harmful combustion products such as polynuclear aromatic hydrocarbons and carbon 
monoxide (aside from nicotine and nitrosamines when cannabis is smoked as a mixture with 
tobacco).   
 
Heat treatment during or before delivery of cannabinoids is necessary to generate CB 
receptor activity, as the cannabinoids occur in the plant as carboxylic acids. They are 
converted into free cannabinoids by decarboxylation at 180 – 200° C. This occurs both on 
smoking and vaporizing. 
 
Eisenberg et al. studied the kinetics of dronabinol in predominantly male neuropathic 
pain patients aged 25 to 69 years (mean age ± SD: 42 ± 14). They used a metered dose 
inhalator (Syqe ®) that vaporized the cannabinoids at 190° C in 497 ms using pharmaceutical 
grade cannabis containing 19.9 % dronabinol, 0.1 % cannabidiol  and 0.2 % cannabinol. Each 
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dose contained 15.1 ± 0.1 mg doses of processed cannabis flos, containing 3.08 ± 0.02 mg 
dronabinol. The efficiency of the THC vaporization process was 52.7 ± 2.7 %. 
They found a mean plasma Cmax  for dronabinol for the entire group of 38 ± 10 ng/mL 
and Tmax occurred after 3 ± 1 minutes. Mean dronabinol AUC0→infinity was 607 ± 200 
ng·min/ml. No measurable plasma levels of the active metabolite (11-OH-THC) were 
monitored within the time frame of the blood sampling (0–120 minutes). (Figure 2) 
(Eisenberg E, Ogintz M, and Almog S, 2014) 
 
 
  
Figure 2. Δ9-THC plasma levels following single dose 
inhalation of 15.1  ± 0.1 mg processed cannabis flos, 
containing 3.08  ± 0.02 mg THC, by using Syqe Inhaler. 
(Eisenberg E, Ogintz M, and Almog S, 2014; reprinted by 
permission of the publisher) 
 
Another study in 18 healthy volunteers compared dronabinol delivery using an electric 
vaporizer (Volcano
®
) compared with smoked cannabis. For both the vaporizer and the 
smoking the study applied the same standardized puff procedure. Subjects were instructed to 
continue puffing until they exhausted smoke or vapour from the delivery device or until they 
had inhaled as much as they could tolerate. Three strengths of cannabis (provided by the US 
National Institute on Drug Abuse) were used both for smoking and vaporizing. The authors 
found that inhalation by vaporizing and by smoking results in equivalent 6-hour AUCs and 
peak plasma-THC concentrations measured at 2 minutes. However, the authors also report 
that the vaporizer was associated with higher plasma-THC concentrations at 30 min and 1 h 
compared to smoking, suggesting that absorption was faster with the vaporizer. Of interest 
was that the systemic dose of THC, as estimated by the plasma AUC, normalized for the THC 
content of the cannabis, varied with THC strength. The AUC becomes relatively lower when 
the strength of the cannabis increases. (Abrams DI et al., 2007) 
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Pharmacokinetics of oral dronabinol (Marinol
®
) 
(US Food and Drug Administration, 2004) 
Absorption 
Dronabinol (administered as Marinol
®
)  is almost completely absorbed (up to 95 %) 
after a single oral dose. It undergoes first pass hepatic metabolism which with high lipid 
solubility leads to only 10-20 % of the dose reaching systemic circulation. 
Distribution 
Dronabinol has a large apparent volume of distribution due to its lipid solubility. It 
also has high plasma protein binding. 
Elimination 
The elimination phase is a two compartment model with an initial half-life of 4 hours 
and a second half-life of 25-36 hours. It is excreted in both faeces and urine. 
Pharmacokinetic interactions 
None identified but there is the possibility of dronabinol displacing other highly protein 
bound medicines. 
Pharmacokinetics of sublingual cannabis extract (Sativex
®
)  
(SPC Anonymous, website) 
Absorption 
Following administration of the spray both THC and cannabidiol (CBD) are absorbed 
and appear in the plasma within 15 minutes. 
Distribution 
The components are quickly distributed and absorbed into body fat. Protein binding is 
high and THC undergoes first pass metabolism in the liver. 
Elimination 
The first order elimination half-life is approximately 2-5 hours for THC and 5-9 hours 
for CBD depending on dose. The process is thought to be biphasic. 
Pharmacokinetic interactions 
Care is advised for co-administration of sedative medicines as there may be an 
additive effect. Strong enzyme inducing medicines such as rifampicin, some antiepileptics 
and barbiturates are not recommend. Medicines affecting cytochrome P systems need to be 
used with caution. 
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Secondary pharmacology 
Effects on cardiovascular system 
Marinol
®
: Palpitations, tachycardia, vasodilation 
Sativex
®
: Alterations in heart rate and blood pressure 
Effects on respiratory system 
None described 
Other pharmacological effects 
Marinol
®
: Anxiety, confusion, dizziness, euphoria, hallucinations, paranoid reaction, 
somnolence. Nausea & vomiting.  
 
Sativex
®
: Anxiety, illusions, changes in mood, paranoia, confusion, hallucinations and 
delusional beliefs 
Routes of administration 
Non-medical use 
Non-medical use of cannabis and cannabis resin is usually by smoking as a cigarette, 
pure, or mixed with tobacco. Oral forms such a mixed in baking products (“space cake”), in 
butter or chocolate occur. 
Medical use  
Herbal cannabis: Usually not regulated and can be in various forms. In addition to the 
routes of administration for non-medical use, also use as a herbal tea (with or without butter 
to enhance the bioavailability of the lipophilic cannabinoids) and by inhalation after 
vaporization occur. 
 
Hazenkamp et al. conducted a cross-sectional survey over the internet in five 
languages (German, English, Spanish, French, Dutch). 953 patients (614 male, 339 female) 
with a mean age of 40.7 years from 32 countries completed the questionnaire. Preferred 
modes of use were smoking of cannabis (62.9 %), inhalation of cannabis with a vaporizer 
(23.6 %), oral use of cannabis in baked goods (7.9 %), oral use of cannabis as a tea (2.4 %), 
and oral use of dronabinol/Marinol
®
 (1.8 %). No significant differences in preferred modes of 
use were found in correlation to symptoms or diseases. (Hazekamp et al., 2011) 
 
Marinol
®
: capsules of 2.5 mg, 5 mg or 10 mg dronabinol for oral administration.  
 
Sativex®: oromucosal spray (each containing 2.7 mg delta-9-tetrahydrocannabinol and 
2.5 mg cannabidiol in 100 microliters). 
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Dosages 
Non-medical use 
The average amount of cannabis in a joint (“spliff”) equates to between 6 and 10 mg 
THC.  People who have used a lot and so developed tolerance may use more. 
Medical use  
Herbal cannabis: Usually not regulated; medical patients will titrate their intake 
depending on the relief of their complaints. They do not usually strive for a high (in 
fact many stop using it if the get high as they do not like the effect). 
Marinol
®
: 2.5 mg to 20 mg daily. 
Sativex
®
: 1-12 spray doses per day (equivalent to 2.7 – 32.4 mg dronabinol and 2.5 –
30 mg cannabidiol). 
5. Experimental toxicology 
In recent years the toxicology of cannabis has been studied more systematically than 
in the past through the research on new pharmaceutical preparations. In the past, many studies 
claimed to have some outcome, but some of the studies did not even declare the THC-content 
of the cannabis which was used, making them less meaningful. With a number of companies 
doing research for having a product approved for medical purposes, “cleaner” research has 
become available. It is for this reason that this section draws with emphasis on studies which 
have been conducted for the market application of Sativex
® 
, which is currently the single 
cannabis product having market authorization. 
Animal studies 
Cannabis is a remarkably safe substance in terms of its acute toxic effects. THC is the 
component of cannabis which has the highest direct toxicity in all animals so far tested. In 
addition to older studies of cannabis and THC the recent introduction in many countries of the 
pharmaceutical preparation Sativex
®
 (a solution containing a balanced mixture of THC and 
cannabidiol, see Section 11) has provided considerably more safety data as per current 
medicine development guidelines (these data are in italics in the following sub-sections).  
  
Single-dose toxicity 
The cause of death in experimental animals is usually respiratory suppression 
(Rosencrantz, 1983). The LD50  on intravenous administration is 40 mg/kg in the rat, but 
phylogenetically higher animals are less susceptible so the LD50 is around 130 mg/kg in the 
dog and monkey (Rosencrantz H, 1983; Rosencrantz H, Fleischman RW and Grant RJ, 1981).   
Repeated-dose toxicity 
The SPC for Sativex
®
 reports “Effects in non-clinical studies were observed only at 
exposures considered sufficiently in excess of the maximum human exposure indicating little 
relevance to clinical use”. (Anonymous, website) 
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Reproduction function 
The SPC for Sativex
®
 reports “Reprotoxicity studies carried out with the THC and 
CBD extracts present in Sativex showed no adverse effects on either male or female fertility in 
terms of numbers of animals mating; number of fertile males and females, or on copulation or 
fertility indices. There were reduced absolute weights of epididymides, with a "no-effect" 
dosage level of 25 mg/kg/day (150 mg/m
2
) for male fertility. Data from the literature have 
shown negative effects of THC and/or CBD on sperm number and motility.” 
Embryo-foetal and perinatal toxicity 
In studies in animals, as expected, due to the lipophilic nature of cannabinoids, 
considerable levels of cannabinoids were found in the maternal breast milk. Following 
repeated dosing, cannabinoids are concentrated in breast milk (40 to 60 times the plasma 
level). Doses in excess of normal clinical doses may affect growth rates of breast-fed infants. 
(Astley SJ and Little RE, 1990) 
 
More recent data in the The SPC for Sativex
®
 reports “The "no-effect" dosage levels 
for effects on early embryonic and fetal survival, in rat studies, were approximately 1 
mg/kg/day (6 mg/m
2
), which is close to or less than the likely maximum human dosage level of 
Sativex.  There was no evidence to suggest any teratogenic activity in either rats or rabbits at 
dosage levels considerably in excess of likely human maximum dosage levels. However, in a 
rat pre- and post-natal study, pup survival and nursing behaviour were impaired at doses of 2 
and 4 mg/kg/day (12 and 24 mg/m
2
 ] respectively. It should be noted that though this may be 
due to a change of taste in the milk rather than an effect of cannabis on the neonate. (Chao FC 
et al., 1976) 
Mutagenic and carcinogenic potential 
This area has been subject to significant research interest in an attempt to discover 
evidence that smoking cannabis could be carcinogenic. The available evidence suggests that 
cannabis smoked alone (that is without tobacco) has a low potential of lung cancer, but when 
used mixed with tobacco the risks from tobacco become apparent. However, because it burns 
at a lower temperature than tobacco leaf, cannabis may reduce the toxicity of tobacco (UK 
Home Office unpublished research). The evidence from Sativex
®
 licensing data and post-
marketing surveillance shows this formulation meets current pharmaceutical safety criteria of 
low/zero carcinogenic risk and there is no reason to suppose other non-smoked forms of 
cannabis will behave differently.  It is important to note that there are a number of anecdotal 
reports that cannabis may have anticancer activity. One clinical trial showed THC efficacy in 
a gliomas (a form of brain tumour).(Arney K, 2012; Guzmán M et al., 2006.) 
Immunotoxicity 
This has been a highly controversial area in years gone by in an attempt to justify the 
continued ban of cannabis or to justify its medical use. More recently a role has been 
postulated because of the presence of CB2 receptors on immune cells. However no clear 
evidence of impact in either direction has been forthcoming and the growing Sativex
®
 data 
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shows no signal of concern re effects to alter in any way immune function. Indeed, there is 
evidence that it can reduce damage in disorders where over-inflammation is a problem e.g. 
ulcerative colitis (http://www.gwpharm.com/inflammation.aspx)  
Neurotoxicity  
Cannabis does not appear to have any significant effects on brain morphology even 
when used for many years. In terms of brain activity and connectivity some studies have 
found increase while others found decrease. However, there is  no clear meaning in terms of 
their explaining functional changes described in the sections below on cognitive and other 
brain functions. (Weiland BJ et al., 2015) 
Human studies 
For obvious ethical reasons there is no experimental evidence to determine a lethal 
dose in humans. Nor is there any clinical evidence, since there have been no proven cases of 
death directly attributable to cannabis poisoning. Extrapolating from the monkey data of 
130 mg/kg mentioned above suggests that the lethal human dose of then the toxic dose of 
THC in a 70 kg adult would be around 9,1 gram THC. In a person of 70 kg, this relates to 
32.5 grams of cannabis with a very high THC content (28 %), 60.5 gram of cannabis with an 
average THC content (15 %), or 114 gram of cannabis low on THC (8 %).  
 
The usual dosing of cannabis delivers around 10 mg so this gives a safety ratio (lethal 
dose to recreational/therapeutic dose) of around 10,000 times in non-tolerant users. In 
comparison, the safety ratio for alcohol is about 10 times and heroin 5 times. Cannabis is 
therefore orders of magnitude safer on acute administration than most other psychoactive 
substances used non-medically. 
Pregnancy 
There is little if any evidence that cannabis use in pregnancy has significant effects on 
the fetus. If there was a meaningful effect the extensive increased in use of cannabis in the 
past 50 years would surely have revealed an association.  
Lactation 
Available pharmacodynamics / toxicological data in animals have shown excretion of 
THC and its metabolites in milk. (see Embryo-foetal and perinatal toxicity; above in this 
Section) 
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6. Clinical toxicology and adverse reactions in humans 
Clinical experience 
Adverse effects 
Marinol
®
 
Asthenia, palpitations, tachycardia, vasodilation, nausea, vomiting, anxiety, confusion, 
depersonalization, dizziness, euphoria, hallucination, paranoid reaction, somnolence, 
abnormal thoughts. 
 
Sativex
®
 
Dizziness and fatigue stated to be very common. Common effects include Asthenia, 
anorexia, constipation, diarrhoea, nausea, vomiting, anxiety, confusion, depression, dizziness, 
euphoria, hallucination, paranoid reaction, somnolence, abnormal thoughts, blurred vision, 
vertigo. 
Non-medical experience 
Smoking cannabis can lead to respiratory irritation and in rare cases with heavy use 
damage to the lung alveolae leading to cavitation. In Europe it is often smoked mixed with 
tobacco so the toxic effects of both are experienced.  
 
Cannabis increases vascular engorgement in the conjunctiva (red eye). 
Fatal intoxications 
The few deaths in which cannabis has been implicated are mostly in middle-elderly 
men with pre-existent cardiovascular disease that is exacerbated by the cannabis-induced rise 
in blood pressure. 
Non-fatal intoxications 
The effect of cannabis in the brain is a feeling commonly described as being “stoned”. 
The ‘stoned’ experience varies considerably depending on the individual’s prior experience of 
cannabis the setting and the type of cannabis ingested (D’Souza et al., 2008; Morgan et al., 
2010a). Common desired effects include heightened awareness of music, sounds, colours, 
textures and tastes disinhibition, giggliness and increased appetite. (Tyler A, 1986) Such 
alterations in perception and insight can impair judgement and coordination leading to an 
increased risk of accidents particularly if driving or operating complex machinery. Anxiety is 
common especially during the onset of drug effects. In people with pre-existing psychosis, 
cannabis can worsen symptoms such as paranoia and auditory hallucinations. Adolescents 
may be more vulnerable to cannabis-induced harms than adults.  (Curran et al, 2016) In 
healthy controls cannabis intoxication has been used as an experimental medicine model for 
psychosis. (Curran & Morgan, 2014) 
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Cognition, learning and memory 
Acute effects  
Acute effects are transient and seen in the time period during which the individual is 
intoxicated with the drug (e.g. feeling ‘stoned’ for around 5-120 minutes when a spliff is 
smoked). A single dose of cannabis or THC robustly and dose-dependently impairs human 
working and episodic memory. (Curran et al. 2002; Crane et al., 2013) Memory impairments 
occur however the drug is administered, but the onset of effect is more rapid when it is 
inhaled or given intravenously than when it is ingested orally. Specifically, the encoding of 
new memories is impaired during cannabis intoxication and this leads to subsequent deficits 
in recalling these memories; by contrast, the retrieval of old memories that were consolidated 
when not under the influence is unaffected. Cannabis-induced working-memory deficits are 
seen more in the ability to manipulate information while it is ‘online’ (for example, when 
doing mental arithmetic) than in the ability to simply retain it for brief periods (for example, 
when remembering a new password code number before entering). Brain imaging studies 
show THC prevents the increased activity with increased working memory load in 
corresponding brain areas. (Bossong et al., 2012)  
  
These effects on memory are consistent with the extensive preclinical evidence of: the 
amnestic effects of cannabis in animal models; the high density of cannabinoid receptors in 
memory-associated brain regions such as the hippocampus, amygdala and prefrontal cortex 
and observations that THC induces disruption of plasticity in the hippocampus.  
Some studies report acute THC-induced impairment of behavioural inhibition and 
increases in impulsivity, but findings on attention, decision-making and risk-taking tasks are 
mixed and task-dependent. (Crane NA et al., 2013; Crean RD, Crane NA and Mason BJ, 
2011). There is also some evidence that acute effects may vary depending on an individual’s 
previous level of use of the substance. Tolerance to the memory-impairing and psychomotor 
effects of acute THC has been shown in individuals who use the cannabis more than once a 
week, probably reflecting a downregulation of cortical CB1Rs. (D’Souza DC et al., 2008; 
Ramaekers JG et al., 2011)  
 
There is some evidence that the acute memory-impairing effects of THC can be 
lessened when individuals smoke cannabis containing high levels of CBD. (Morgan CJ et al., 
2010; Englund A et al., 2013) One study showed CBD alone enhanced fear extinction 
learning in humans. (Das RK et al., 2013) A recent cross-sectional study found that CBD 
appeared to protect against the effects of THC on hippocampal volume loss. (Yucel et al., 
2016).   
Long-term effects 
Although in several countries legislation will enable new studies of medical cannabis 
to use prospective, randomized controlled trial designs, to date studies of the neurocognitive 
effects of long-term use of cannabis have relied mainly on retrospective, self-reported drug 
use by people who use cannabis non-medically. More objective indices of drug use can be 
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obtained through hair samples, although these are also somewhat limited (e.g. influenced by 
hair dyes) and have been rarely used in studies. (Han E, Chung H and Song JM, 2012) Long-
term impairments in memory have been reported mainly in frequent, heavy users, but 
confounding factors make it difficult to establish any cause-effect relationships between 
cannabis use and neurocognitive function. Such factors include baseline cognitive function 
prior to drug use; use of other cognitively impairing drugs like alcohol; types of cannabis 
used; age at which use started; and mental health problems, including depression and cannabis 
dependence. 
The most consistently reported long-term effects are impairments of encoding new episodic 
memories, with some studies finding persistent deficits in the first few days of abstinence.  
There is increasing agreement that these deficits are no longer seen when the individual stops 
using cannabis for 28 days. (Crane NA  et al., 2013) Functional neuroimaging studies have 
been mainly cross-sectional and very heterogeneous and it is not possible to infer any 
causative relation between long-term cannabis use and brain changes (cf. systematic review 
by Batalla et al., 2013)    
Age-dependent effects: adolescence and adulthood 
The endocannabinoid (eCB) system has a major role in neurodevelopmental and 
maturational processes (including synaptic pruning and white-matter development), and these 
processes are especially prevalent during adolescence. As cannabis affects the functioning of 
the eCB system, the human brain may be more vulnerable to psychoactive substances at the 
time when use of cannabis often begins. 
 
Preclinical studies have shown that a single dose of THC results in greater 
impairments to spatial and non-spatial learning in adolescent rats than in adult rats. (Cha et 
al., 2006) Similarly repeated THC has a more negative impact on adolescents, producing 
persisting impairments in memory that are not seen with the same treatment in adult rats. 
(Schneider M and Koch M, 2007) When THC was repeatedly administered over 6 months to 
adolescent monkeys in doses that corresponded well to human self-administration 
(approximately 1–2 joints, 5 days per week), the usual pattern of accuracy improvements on a 
test of spatial working memory was blunted. (Verrico CD et al., 2014) Thus, the persistent 
effects of THC on cognition in animals are more evident when exposure coincides with the 
developing adolescent brain.  
 
From studies with humans there is some evidence that neurocognitive function and 
aspects of brain architecture are more disrupted by cannabis when individuals start using it 
during adolescence, although there is little longitudinal research and a scarcity of direct 
comparisons with adult users (Curran HV et al., 2016). It is generally difficult to say whether 
differences between cannabis users and non-users in cognitive function and/or brain 
structure/function are consequences of cannabis use rather than existing prior to use. (Jager G 
et al., 2010; Curran HV et al., 2016) In terms of neurocognitive function, individuals who 
started using cannabis during adolescence have been reported to have greater deficits in 
visuospatial attention, verbal fluency and inhibition than do those who start in adulthood. 
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(Ehrenreich H et al., 1999; Gruber SA et al., 2012) A recent study directly compared the acute 
effects of cannabis in adolescents (16-17 year old males) and in adults (24-28 year old males). 
(Mokrysz C et al., in press). This is the first study of its kind and used a placebo-controlled, 
double-blind cross-over design. On active cannabis, working and episodic memory 
impairment was greater in adults than adolescents. By contrast, cannabis impaired response 
inhibition accuracy in adolescents but not in adults. These contrasting profiles of adolescent 
resilience and vulnerability show some degree of translation from preclinical findings, and 
may contribute to escalated cannabis use by human adolescents.  
Effects persisting after stopping use. 
Several studies of long-term effects after an individual stops using cannabis are 
converging to show that cognitive impairments do not persist beyond 4–6 weeks after 
abstinence
 
(Pope HG et al., 2001; Schreiner AM and Dunn ME, 2012). Similarly, using 
positron emission tomography (PET) imaging, one study demonstrated that chronic cannabis 
users showed a downregulation of cortical CB1Rs that correlated with years of use. (Hirvonen 
J et al., 2012) After ~4 weeks of continuously monitored abstinence from cannabis at a secure 
research unit, their CB1R density returned to control levels, further supporting recovery within 
4 weeks, and even, according one recent study, after as little as 2 days (D’Souza DC et al., 
2015)  
Cannabis, IQ and educational achievement 
To date, there have been three large prospective cohort studies that have assessed the 
relationship between cannabis use and IQ. In a New Zealand birth cohort study of 1,037 
38-year olds born in 1972 or 1973, persistent cannabis dependence was associated with a 
decline of up to 6 IQ points from that measured at age 7-13 years (Meier et al., 2012). The 
decline was particularly evident for those who developed cannabis dependence in 
adolescence, and remained apparent even for those who, at age 38 years, used cannabis less 
than once a week.  
In contrast, a UK birth cohort study of 2,235 15–16-year-old adolescents born in 1991 
or 1992 found that cumulative cannabis use was not associated with a lower IQ compared 
with non-using controls, once IQ measured pre-teen and various potential confounders (in 
particular, the adolescents’ use of cigarettes and alcohol) were accounted for (Mokrysz C et 
al., 2016). Cannabis use was relatively low in this study, with only 72 adolescents reporting 
more than 50 lifetime cannabis exposures.  
A US prospective cohort study of 3,066 17–20-year-olds found no difference in IQ 
change from that measured at age 9-12 years between monozygotic and dizygotic twins 
discordant for cannabis use.
164
 However, there were only 47 discordant twin pairs in which 
the cannabis-using twin had used cannabis frequently (more than 30 cumulative uses, and/or 
daily use), limiting the strength of any conclusions from this study. 
The UK and US studies therefore both suggest that genetic or environmental factors 
drive the observed associations between lower IQ and cannabis use, although both cohorts 
included younger participants with fewer cannabis exposures than did the New Zealand study.  
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To date, all studies have relied on retrospective self-report of cannabis use, have 
ignored possible residual effects of the drug on IQ-test performance and have not addressed 
the potency or variety of cannabis used.   
Several case-control and longitudinal studies have provided fairly consistent evidence 
of associations between adolescent cannabis use and both early school leaving and poorer 
educational performance. (Fergusson DM, Horwood LJ and Beautrais AL, 2003; Silins E et 
al., 2014; Lynskey MT & Hall W, 2000; Townsend L, Flisher AJ and King G, 2007) But the 
mechanisms producing these relationships remain hotly debated. (Verweij KJ et al, 2013) 
Some argue that heavy cannabis use results in cognitive and/or motivational deficits, which in 
turn result in poorer educational attainment. Others claim reverse causality - that poorer 
educational attainment leads to cannabis use (Fergusson DM, Horwood LJ and Beautrais AL, 
2003; Lynskey MT and Hall W, 2000).  
An alternative is that educational attainment and cannabis use may not be causally 
related but instead share common risk factors. (Fergusson DM, Horwood LJ and Beautrais 
AL, 2003; Silins E et al., 2014; Lynskey MT and Hall W, 2000; Townsend L, Flisher AJ and 
King G, 2007)  This is supported by recent analyses showed that adjusting for teenage use of 
other substances attenuated the association between cannabis use and school attainment 
(Mokrysz C et al., 2016.; Hooper SR, Woolley D and De Bellis MD, 2014; Stiby AI et al., 
2015). It is also supported by recent genetic studies that found no difference in early school 
leaving or years of education between both monozygotic and dizygotic twin pairs who were 
discordant for cannabis use. (Verweij KJ et al., 2013; Grant et al., 2012) 
 
  
7. Dependence potential 
Introduction 
The dependence producing potential of cannabis is harder to assess than that of other 
substances. The UN scheduling is particularly relevant for drugs of the opioid class where 
clear scaling of reinforcing potential and self-use in animal models and humans is possible. 
This scaling has led to the defining by the Technical Committee of  the Plenipotentiary 
Committee that negotiated the Single Convention, of the threshold for Schedule 1 as having a 
dependence like codeine or above and Schedule 2 as between codeine and 
dextropropoxyphene. As cannabis does not substitute for these opioids then a simple cross-
reference of dependence potential is not possible. However as stated in Section 13, the 
percentage of users who become dependent on cannabis is significantly less than that for 
alcohol, cocaine, tobacco or Schedule 1 opioids. (Anthony JC, Warner LA and Kessler RC, 
1994; Lopez-Quintero C et al., 2011).  
Reinforcing effects  
The reinforcing effects of cannabinoids in animals depend on species, route of 
administration and experimental design. Rats will perform a behavior such as level pressing to 
receive THC or CB1R agonist infusions directly into the brain. (Braida D, Iosue S, Pegorini S 
and Sala M, 2004; Zangen A  et al., 2006) However, it is difficult to get rats to perform for 
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intravenous THC self‑administration although this does occur in squirrel monkeys. (Justinova 
Z et al, 2005;  Fattore L et al., 2001). The rewarding effects of THC in rats are dose-
dependent and follow an inverted U-curve whereby large doses are less rewarding than 
medium doses; this has been shown in various experimental paradigms (e.g. conditioned place 
preference, intracranial self-stimulation. (Braida D, Iosue S, Pegorini S and Sala M, 2004; 
Gardner EL et al., 1988; Sanudo-Pena MC et al., 1997; Cheer JF, Kendall DA and Marsden 
CA, 2000) CBD does not influence the acute reinforcing effects of cannabis or the rewarding 
feeling of being ‘stoned’. (Morgan CJ et al., 2010; Haney M et al., 2015) 
 
In humans, THC produces the same inverted U-curve in terms of rewarding effects. 
THC produces the effects that users seek and so is the key reason for using cannabis. Human 
PET studies indicate that THC can increase dopamine release in the striatum although to a far 
lesser extent than do other recreational drugs, and not in all studies. (Bossong MG et al., 2015 
Nutt DJ et al., 2015) THC-induced increases in opioid peptide release may   also contribute to 
the rewarding effects of cannabis. (Manzanares et al., 1998; Valverde O et al.,  2001) 
Tolerance  
Tolerance to cannabis and to THC occurs in both animal models and humans. Rats 
chronically exposed to THC show reduced CB1R function throughout the brain which persists 
for days after THC treatment and then recovers; behavioural tolerance is also evident. 
(González S, Cebeira M and Fernández-Ruiz J, 2005; Hoffman AF, Oz M, Caulder T  and 
Lupica CR, 2003) Similarly, humans who use cannabis chronically have been repeatedly 
shown to have CB1R downregulation. (Hirvonen J et al., 2012; D’Souza DC et al., 2015) 
 
Importantly, as with rodents, this effect reverses within weeks of humans stopping 
cannabis use (Hirvonen J et al., 2012) . Behavioural tolerance is also evident in humans and 
there is evidence of tolerance to the adverse cognitive effects of cannabis (D’Souza DC et al., 
2008; Ramaekers JG et al., 2011) 
Dependence and withdrawal 
Although much research on cannabis and mental health has focused on psychosis, 
dependence is a far more common problem: we estimate that people who try cannabis are 
9-fold more likely to become dependent on it than to develop psychosis in their lifetime 
(Moore TH et al., 2007; Kessler RC et al., 1994; Lopez-Quintero C et al., 2011).   
The term ‘dependence syndrome is defined by ICD-10 as being a cluster of 
physiological, behavioural, and cognitive phenomena in which the use of a substance or a 
class of substances takes on a much higher priority for a given individual than other 
behaviours that once had greater value. A central descriptive characteristic of the dependence 
syndrome is the desire (often strong, sometimes overpowering) to take the psychoactive 
substances (which may or not have been medically prescribed), alcohol, or tobacco. 
Symptoms use in ICD-10 diagnosis include tolerance, withdrawal, a strong desire or sense of 
compulsion to take the substance; difficulties in controlling substance-taking behaviour, 
progressive neglect of alternative pleasures, persisting with substance use despite clear 
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evidence of overtly harmful consequences In the Diagnostic and Statistical Manual for 
Mental Disorders, fourth edition, text revision (DSM-IV-TR), clinical problems associated 
with cannabis use were previously diagnosed as ‘cannabis abuse’ or ‘cannabis dependence’ In 
the most recent version (DSM-5) these categories were amalgamated into a single diagnosis of 
‘cannabis use disorder’ (CUD).   
A specific cannabis withdrawal syndrome is well recognized and affects around 50 % 
of daily users upon cessation of use, and typically begins 1–2 days after cessation, peaks at 2–
6 days and remits at 1–2 weeks. (Budney AJ et al., 2004) Prominent symptoms include 
craving, sleep problems, nightmares, anger, irritability, dysphoria and nausea. (Allsop DJ et 
al., 2011) Cannabis withdrawal symptoms correlate with reductions in CB1R availability 
during acute abstinence (D’Souza DC et al, 2015) and can be alleviated by THC in a dose-
dependent manner. (Budney AJ et al., 2007) Cannabis is frequently rolled with tobacco in 
‘joints’ and many users also smoke cigarettes. In daily users of cannabis and tobacco, 
individual withdrawal effects appear similar for both drugs; combined withdrawal produces 
stronger effects than does withdrawal for either one alone. (Budney AJ et al., 2004) 
Vulnerability factors 
 Only a minority of cannabis users become dependent; therefore, what factors must 
predict vulnerability? Concurrent tobacco use has been identified as a risk factor, as have 
early adolescent onset and frequent (especially daily) use. (Coffey C et al., 2003; Hines LA et 
al., 2016; Hindocha C et al., 2015; Chen C-Y, O’Brien MS and Anthony JC, 2005) Males 
typically have an earlier opportunity to use cannabis, a greater risk of dependence and a faster 
progression from first opportunity of use to dependence. (Coffey C et al., 2003; Hines LA et 
al., 2016) These findings are consistent with normative data from European treatment 
services: the mean age at first cannabis use is 16, the mean age of first treatment is 24, and 
83 % of treated individuals are male. (European Monitoring Centre for Drugs and Drug 
Addiction, 2015) 
 
Interestingly, a three-year prospective study of daily users found that variables related 
directly to cannabis use did not predict transition to dependence; more important were current 
factors such as living alone, coping motives and negative life events (such as having had a 
major financial crisis). (Van der Pol P et al., 2014). A meta-analysis of 24 twin studies 
suggested that genetic influences account for 55 % of the vulnerability to cannabis 
dependence, with shared environmental factors and non-shared environmental factors 
accounting for much lower proportions (17.5 % and 27.5 %, respectively). (Verweij KJ et al., 
2010) 
Cannabis, anxiety and depression  
Like most dependencies, cannabis dependence is often comorbid with other mental 
health problems. Epidemiological evidence indicates a possible association between regular 
cannabis use and the development of anxiety and depression. However, the evidence is more 
mixed and less consistent than that between cannabis use and psychosis. (Moore et al, 2007) 
One recent study compared the mental health of individuals who were dependent on cannabis 
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(according to the DSM-IV) with that of non-dependent cannabis users who had similar 
patterns of cannabis use. Only the dependent users had depression and anxiety problems (Van 
der Pol et al., 2013). Studies of young (16–24-year-old) daily cannabis users have found that 
levels of THC in hair are significantly associated with self-reported levels of both depression 
and anxiety (Morgan C et al., 2012). 
The interconnectedness of cannabis use, mental-health problems and cognitive 
functioning is important. It is inherently difficult to determine causality in the type of studies 
discussed above because factors besides cannabis use (e.g. premorbid cognitive and emotional 
function) may be directly associated with risk of mental illness. Such factors could predispose 
an individual both to mental illness and to using cannabis, and the combination of these 
disorders would in turn increase their impact upon cognitive functioning.  
Cannabis and psychosis  
Nearly 2,000 papers have been published on this topic since 1962, and the pro-
psychotic effects of cannabis have dominated media reporting about this drug. But how clear 
is the link? A number of longitudinal, population-based studies show an earlier first episode 
(Large M et al., 2011) and a roughly two-fold increase in risk of psychosis with regular 
cannabis use (Moore TH et al., 2007). Yet the vast majority of people who use cannabis do 
not develop psychotic disorders and many people diagnosed with such disorders have never 
used cannabis. 
More agreement is found in evidence that heavy cannabis use may mean that young 
people who are vulnerable to psychosis develop the disorder when they may not have 
otherwise done so. Converging data suggest that this may have a genetic basis, with certain 
polymorphisms of the gene encoding AKT1 potentially conferring risk of psychosis following 
smoking cannabis acutely and chronically. (Morgan CJA et al., 2016; Di Forti M et al., 2012; 
Van Winkel R et al., 2011).  
The type of cannabis used has recently been found to impact on risk of psychosis: self-
reported hash use, even daily, is not associated with increased risk of psychosis, whereas self-
reported daily use of skunk (which contains high levels of THC and negligible amounts of 
CBD) is associated with a five-fold greater chance of having schizophrenia (Di Forti M et al., 
2015). Several studies using objective biological markers of use have shown that CBD 
reduces the psychosis-like effects of THC (Morgan C and Curran HV, 2008; Morgan C et al., 
2011)  
How cannabis interacts with the brain to increase psychosis risk is unclear. 
Disruptions in the brain’s endocannabinoid system have been found in psychosis and may 
provide clues as to the pro-psychotic impact of cannabis. Anandamide is a naturally occurring 
CB-receptor agonist.  Higher levels of anandamide in the cerebrospinal fluid have been 
associated with lower psychotic symptoms in individuals diagnosed with schizophrenia in 
individuals classified as having prodromal schizophrenia who do not smoke cannabis and in 
cannabis users without a diagnosis of schizophrenia. (Leweke FM et al., 1999;  Koethe D et 
al., 2009; Morgan CJ et al., 2013) Anandamide is known to have a neuromodulatory role in 
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the brain; thus, during prodromal or first-episode psychosis, anandamide may be increased to 
attempt to control dysregulated brain dopamine. (Di Marzo V, 2008) 
8. Therapeutic applications and extent of therapeutic use 
The place of cannabis/cannabinoids in medical care 
Cannabis and its derivatives may have a place in the treatment of three difficult 
conditions: chronic pain including fibromyalgia, chemotherapy induced nausea and vomiting, 
and the symptoms of multiple sclerosis.  
 
All these conditions can be challenging for the clinician to manage; existing therapies 
have limited effectiveness. In chronic pain, around one person in six will respond to 
antidepressants or antiepileptics. Opioids are frequently tried but are largely ineffective 
despite high doses. Neuropathic pain caused by HIV/AIDS or chemotherapy remains 
extremely resistant to any treatment. Nausea and vomiting for highly emetogenic 
chemotherapy regimens is very difficult to manage and is distressing for patients. Similar 
problems exist in managing the symptoms, especially spasm, for multiple sclerosis sufferers.  
In all of these conditions, there may be a role for standardized cannabis based 
products.  
Evidence of effectiveness  
Many organizations including WHO use a hierarchy of evidence to support or deny 
the use of certain medicines. Systematic reviews of randomized controlled trials (RCTs) or 
large RCTs are considered the highest level.  
 
Searches were carried out up to the end of August 2016 using Medline, Embase, the 
Cochrane Library and the IACM database. Studies involving healthy volunteers have not been 
considered. 
 
An extensive search of the medical databases using a variety of terms for cannabis and 
its derivatives identified nine good quality systematic reviews for seven areas of medicine 
namely: 
  
 chemotherapy induced nausea and vomiting,  
 chronic pain,  
 dementia,  
 fibromyalgia,  
 rheumatoid arthritis,  
 symptoms of HIV/AIDS, and  
 treatment of spasticity in multiple sclerosis.  
 
When describing these studies, it is not always easy to distinguish between cannabis, its 
preparations (e.g. nabiximols) and other cannabinoids (e.g. dronabinol, which is a constituent 
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of cannabis, but has also its own listing in the United Nations Convention on Psychoactive 
Substances). Moreover, some synthetic cannabinoids, such as nabilone, are sometimes 
included in the study designs. 
 
The IACM database contained two review articles (not strictly systematic) for clinical 
studies published between 2005 and 2009 and 2010-2014. (IACM database, website) A search 
of the Central database of the Cochrane Library (search date 23.8.16) produced 1142 studies 
tagged as RCTs. (Cochrane Library, website)  
Systematic reviews 
These are briefly described to show that there is a good evidence base in some 
conditions for the medicinal use of cannabis derivatives. 
 
1. Chemotherapy induced nausea and vomiting. 
Two reviews described the use of cannabis derivatives or smoked cannabis for treating 
nausea and vomiting.  
 
The first by Machado published in 2008 included 30 RCTs (1,719 participants). It 
concluded that dronabinol was statistically and clinically more effective than neuroleptics 
with an Number Needed to Treat (NNT) of 3.4 to prevent one episode of vomiting (A NNT 
closer to one is better, a higher NNT is worse). They concluded that the synthetic 
cannabinoids levonantradol and nabilone were not superior to neuroleptics. (Machado Rocha 
FC et al., 2008)  
 
A later Cochrane review by Smith in 2015 included 23 RCTs (1326 participants) using 
stricter inclusion criteria than Machado. The review showed that cannabinoids were superior 
to placebo but there was no difference in efficacy between cannabinoids and 
prochlorperazine. In that scenario, participants reported a preference for cannabinoids in 
cross-over studies. (Smith LA et al., 2015)  
 
2. Chronic pain 
Two reviews examined evidence for chronic pain and neuropathic and multiple 
sclerosis (MS) related pain. (Martin-Sanchez E et al., 2009; Iskedjian M et al., 2007) 
 
The review by Martin-Sanchez et al. looked at chronic pain of greater than six months 
assessing cannabis preparations administered by any route compared to a placebo group. 
Eighteen RCTs (809 participants) were included. The trials showed a significant reduction in 
mean pain scores but also an increase in CNS related adverse events specifically euphoria, 
altered perception, motor function or cognitive function but not dysphoria. (Martin-Sanchez E 
et al., 2009)  
 
The second review by Iskedjian published in 2007 included seven RCTs 
(298 participants) of cannabis derivatives for MS related pain or similar neuropathic pains. 
Cannabis preparations were more effective than placebo in reducing pain scores with the 
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largest reduction achieved with cannabidiol/THC buccal spray (nabaximols). Cannabidiol and 
dronabinol separately also showed effectiveness. Dizziness was the most commonly reported 
adverse effect. (Iskedjian M et al., 2007)  
 
3. Dementia 
This Cochrane review published in 2009 by Krishnan et al. identified one study of 15 
participants. The authors concluded that there was a lack of evidence to support the use of 
cannabinoids for dementia. (Krishnan S et al., 2009)  
 
4. Rheumatoid arthritis (RA) 
Just four RCTs of 141 participants were included in a Cochrane review by Richards et 
al. published in 2012. The authors looked at neuromodulators for pain management in RA. 
One small low quality trial of 58 participants assessed oromucosal cannabis against placebo 
and found a small significant difference in reduction of pain. (Richards BL et al., 2012) 
However the study is too small to be reliable. 
 
5. Symptoms of HIV/AIDS  
Another Cochrane review by Lutge et al. looked at the use of cannabis for reducing 
morbidity and mortality in HIV/AIDS. Seven studies (330 participants) were included but the 
studies were small and of short duration and failed to show benefit. (Lutge EE et al., 2013)  
 
6. Treatment of spasticity in multiple sclerosis 
A review by Lakhan et al. in 2009 included 6 RCTs (820 participants). The 
intervention was a combined extract of THC and cannabidiol. The studies showed a reduction 
in spasticity and improved motility in patients with MS. The authors report that adverse 
effects were generally well tolerated. (Lakhan SE and Rowland M, 2009)  
 
A Cochrane review by Mills et al. published in 2007 specifically looked at treatments 
for ataxia in MS. Ten studies of different interventions were included but only 2 studies (29 
participants) used cannabis making it impossible to draw any meaningful conclusions. (Mills 
RJ et al., 2007)  
Primary Studies 
1. The IACM database (IACM database, website) 
Two review articles published in the journal ‘Cannabinoids’ cover the time period 
from 2005 to 2014 in separate papers. Combining the tables (Table 2) gives a good indication 
of the size of the literature around the use of cannabis and related products in various 
conditions. Six small studies (125 participants) examined the use of smoked cannabis and two 
studies (344 participants) reported on studies of oral cannabis extract (herb). 
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Table 2. Overview of the size of the literature around the use of 
cannabis and related products in various conditions 
Condition No of studies  Total no of participants 
Chronic and /or neuropathic pain 22 1842 
Multiple sclerosis 15 2815 
HIV/AIDS 4 118 
Irritable bowel syndrome 3 133 
Nausea and vomiting 3 246 
Other conditions 16 438 
 
2. Central database of the Cochrane Library (Cochrane Library, website) 
Seventy two studies of the medicinal use of cannabis were identified on the Central 
database out of over 1000 citations. The remainder generally describe studies dealing with 
dependence related issues. Six studies describe the use of smoked or vaporized cannabis with 
five in patients with chronic neuropathic pain (166 participants) and one in multiple sclerosis 
(37 participants). All small studies report a significant reduction in pain intensity compared to 
placebo. 
Extent of therapeutic use 
Currently, medical use of cannabis is allowed in a number of countries. In  2000,  total  
production  was  1.3  tonnes;  by  2014  it  had  increased  to  56.9  tonnes. (International 
Narcotics Control Board, 2015)  The main producer countries (2012) are Canada (75 % of the 
global production), the United Kingdom (18 %) and Israel (5 %). (International Narcotics 
Control Board, 2014) Table 3 presents the actual legal consumption for 2014 as reported by 
the countries to INCB. This is mainly for medical purposes, but also includes research. It  
should be noted that not all countries submitted their reports. 
 
Table 3. Legal cannabis consumption by country in kg (2014)  
(International Narcotics Control Board, 2015)   
Canada 48,649  Spain 14 
Israel 5,483  United States 11 
United Kingdom 2,230  Hungary 3 
Italy 548  Bulgaria 2 
Netherlands 316  Czech Republic 2 
Switzerland 72  Lithuania 2 
Austria 49  Germany 1 
Portugal 28  Gibraltar 1 
Denmark 15    
 
In the United States, the states of Alabama, Alaska, Arizona, California, Colorado, 
Connecticut, Delaware, Florida, Hawaii, Illinois, Iowa, Kentucky, Louisiana, Maine, 
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Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, 
New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, 
Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, 
Washington, Wisconsin, Wyoming and the District of Columbia approve and regulate the 
medical use of cannabis, although it remains prohibited under federal law. (NORML, website)  
9. Listing on the WHO Model List of Essential Medicines 
Not listed. 
10. Marketing authorizations (as a medicine) 
Sativex
®
 (GW Pharmaceuticals plc., Cambridge, United Kingdom; marketed by 
Bayer) is a standardized extract of cannabis (nabiximols USAN). This is a mixture of two 
cannabis extracts containing fixed concentrations of dronabinol and cannabidiol. Each ml 
contains 38-44 mg and 35-42 mg of two extracts (as soft extracts) from Cannabis sativa L., 
folium cum flore (Cannabis leaf and flower) corresponding to 27 mg delta-9-
tetrahydrocannabinol and 25 mg cannabidiol.  Additional constituents include related 
cannabinoids and non-cannabinoid components in small amounts. It is provided as 
oromucosal spray. A unit dose is 100 microlitres sprayed into the mouth, giving a dose of 2.7 
mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol. 
 
The cannabis is produced and extracted in the United Kingdom. Sativex
®
 is licensed as 
treatment for symptom improvement in adult patients with moderate to severe spasticity due 
to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity 
medication and who demonstrate clinically significant improvement in spasticity related 
symptoms during an initial trial of therapy. 
 
Sativex
®
 has been approved as a medicine in 28 countries (including Austria, 
Australia, Belgium, Canada, the Czech Republic, Denmark, Finland, Germany, Hungary, 
Iceland, Ireland, Israel, Italy, Luxemburg, the Netherlands, New Zealand, Norway, Poland, 
Portugal, Slovakia, Spain, Sweden, Switzerland, and the United Kingdom).  
Sativex
®
  is also in Phase 3 for the indication of treatment of cancer pain. 
 
Dronabinol (INN) is a constituent of cannabis which is separately controlled under the 
UN Convention on Psychotropic Substances. Dronabinol has been reviewed previously by the 
ECDD, for the last time in 2007. (World Health Organization, 2006a; World Health 
Organization, 2006b)  It is also a constituent of the medicine Marinol
®
 (2.5 mg, 5 mg, 10 mg), 
which is marketed by AbbVie and licensed in the USA and Canada for management of the 
loss of appetite associated with weight loss in acquired immune deficiency syndrome (AIDS) 
and management of nausea and vomiting associated with cancer chemotherapy in patients 
who have failed to respond adequately to conventional treatments. The dronabinol in 
Marinol
®
 is semi-synthetic, as it is prepared by extracting cannabidiol from cannabis low on 
dronabinol and then converted into dronabinol. (This is related to the controls on the 
cultivation and handling of cannabis high on dronabinol) 
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At least three more companies have four new preparations in the pipeline:  
1. Echo Pharmaceuticals (Weesp, the Netherlands) developed a THC-based product, 
which is in Phase III for multiple sclerosis and in Phase II for Alzheimer’s disease 
and chronic pain. 
2. Echo developed a CBD-based product which is in Phase II for schizophrenia. (cho 
Pharmaceuticals, website) 
3. Syqe medical (Tel Aviv, Israël) developed two types of single-dosage inhalers, one 
of which has selective 100 microgram dosing precision, the other producing a THC 
pharmacokinetic profile with low-interindividual variation of Cmax. See also the 
Subsection Pharmacokinetics of inhaled cannabis. (SYQE Medical, website) 
4. Axim Biotechnologies, Inc. (New York NY, USA) is in the process of developing a 
chewing gum containing cannabinoids for multiple sclerosis and chronic pain and 
expects registration second half of 2018. Clinical trials are conducted together with  
Free University Amsterdam. Research with various other cannabinoid-based 
preparations are ongoing. (Axim Biotech, website ) 
11. Industrial and other use 
Industrial and agricultural uses 
As discussed above, hemp is used for its fibers. Examples of this use are the 
manufacturing of rope, carbon fiber materials (e.g. for car dashboards) and insulation 
materials. Hemp straw is used for covering horse stable floors. 
(The materials used in these applications are outside the Convention’s definition of 
cannabis) 
Nutritional uses 
Hemps seeds are used as such in bread or are pressed for the production of vegetable 
oil. Hemp seed oil has a high content of polyunsaturated fatty acids. If rinsed with water, the 
seeds contain only traces of tetrahydrocannabinol. (The seeds if not accompanied by the 
flower buds are outside the Convention’s definition of cannabis) 
Religious uses 
Cannabis serves as a sacrament in various religions, a few of these are the Rastafari 
movement (Jamaica) and the Church of Santo Daime (Brazil).Wikipedia mentions at least 16 
more religions using cannabis. (Wikipedia, website) 
 
The Rastafari movement, a religion which started in the 1930s in Jamaica, uses 
cannabis (“Ganja”) in a highly ritualized manner during the religious ceremonies. Their focus 
is not on getting high. The use of cannabis during these ceremonies is based on the believe 
that the Tree of Life mentioned in the Bible is cannabis and that several other biblical 
passages further promote its use, such as “Thou shalt eat the herb of the field” (Genesis 3:18), 
“Eat every herb of the land” (Exodus 10:12) and “The herb is the healing of the nations” 
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(Revelation 22:2). (Dufton E, 2015)   (The religious uses of cannabis are inside the 
Convention’s definition of cannabis) 
12. Epidemiology of non-medical use and dependence 
Cannabis is the most commonly used illicit drug. Globally around 182 million people 
(15-64 years old) used cannabis in 2013 for non-medical reasons. (United Nations Office on 
Drugs and Crime, 2015a) There are marked variations across WHO regions in the recorded 
prevalence of cannabis use, and in how and how often countries collect this data. In the USA 
a recent survey (N=596,500) showed cannabis use by adults increased from 10.4 % in 2002 to 
13.3 % in 2014 and this change was associated with a decrease in the perception of risk of 
using the drug 1-2 times per week. However, it is noteworthy that there was no increase in 
cannabis use disorders which remained around 1.5 % across the years. (Compton M  et al., 
2016) In the European Region, it was estimated that 16.6 million young people (15-34 year 
olds) used cannabis in the last year which corresponds to 11.7 % of this age group. (European 
Monitoring Centre for Drugs and Drug Addiction, 2016) Of the adult population (15-64 year 
olds) in Europe, 22.1 million (6.6 %) used the previous year and 83.2 million 24.8 % used in 
their lifetime. (European Monitoring Centre for Drugs and Drug Addiction, 2016) There is 
considerable variation across countries in cannabis use (e.g. lifetime prevalence by 15-24 year 
olds is over 40 % in France, the Czech Republic and  Denmark but less than 10 % in Greece, 
Malta and Romania. (European Monitoring Centre for Drugs and Drug Addiction, 2016) As 
with other drugs, rates of cannabis use are more than twice as high in men than in women and 
higher in more urban, densely populated areas. Similarly, like other illicit substances, use is 
highest among 15-24 year olds, with 16 being the median age of first use of cannabis in most 
European countries. (cf. Curran et al. HV, 2016). 
 
The chances of becoming dependent on cannabis after lifetime exposure is 8.9 %, 
which is considerably lower than for alcohol (22.7 %), tobacco (67.5 %) or cocaine (20.9 %). 
(Lopez-Quintero C et al., 2011) At the same time, the clinical need for treatment of cannabis 
dependence is substantial and increasing in North America, Europe and Oceania. (United 
Nations Office on Drugs and Crime, 2015.)  Across Europe, cannabis now accounts for more 
first-time entrants to drug treatment services than any other illicit drug, reflecting the greater 
prevalence of use of cannabis than other illicit substances. (European Monitoring Centre for 
Drugs and Drug Addiction., 2015) One study estimated that 1.8 % of 14-17 year olds in 
Europe meet clinical criteria for cannabis dependence. (Wittchen H-U et al., 2011) 
 
  The majority of even daily cannabis users do not become dependent on the drug.  A 
prospective study of  600 18-30 year old daily or near daily  cannabis users in the Netherlands 
found 37.2 % fitted dependence criteria over a 3 year assessment period. (Van der Pol P et al., 
2013) However, what predicted transition to cannabis dependence were those young people’s 
current problems (e.g. living alone, coping motives for cannabis use, number and type of 
recent negative life events) and not the extent of cannabis use. 
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13. Nature and magnitude of public health problems related to non-
medical use and dependence 
Mental health problems are the major public-health concern with cannabis.  These are 
cannabis dependence, increased risk and earlier onset of psychosis and depression (see 
previous sections on these). Driving while under the influence and respiratory problems from 
smoking are other public-health concerns. 
Driving 
Numerous laboratory studies have shown that acute cannabis or THC dose-
dependently impair concentration, reaction time and perceptual-motor co-ordination. These 
impairments are more marked in occasional than regular cannabis users. Epidemiological 
studies indicate that cannabis users who drive when intoxicated double their risk of a car 
crash (Asbridge et al., 2012). This risk increases significantly if drivers also have elevated 
alcohol levels (Hartman & Huestis, 2013). One of the biggest research projects ever carried 
out in 9 EU countries on drugs and driving found that 2 ng/ml THC in whole blood (3.8 ng/ml 
THC in serum) caused impairment equivalent to 0.5 g/l BAC which is the legal limit for 
driving in many countries. (European Monitoring Centre for Drugs and Drug Addiction, 
2012b) There is evidence that cannabis users adapt their driving behaviour when under the 
acute influence of the drug and become more cautious. Overall, the existing evidence points 
to a small causal impact of cannabis on injury through traffic accidents. (World Health 
Organization, 2016) The effect is particularly small compared to that of alcohol. 
Respiratory problems 
A number of studies have investigated whether smoking cannabis increases the risk of 
chronic obstructive pulmonary disease (COPD). Most have found that although the risk of 
chronic bronchitis is increased, there is no increased risk of COPD. Cannabis-only smokers 
are more likely to report cough, sputum and wheezing than controls who do not smoke and 
those who subsequently quit using the drug show reductions in those same symptoms 
compared with those who continue use. (Tashkin DP, Simmons MS and Tseng CH, 2012; 
World Health Organization, 2016) In many parts of the world, cannabis is smoked mixed with 
tobacco and this renders the user subject to the many negative health risks of tobacco 
smoking. 
14. Licit production, consumption and international trade 
Non-medical use 
In 2014, Uruguay legalized the production and use of cannabis for medical and non-
medical purposes. Individuals need to register with a state agency, the Institute for Regulation 
and Control of Cannabis (IRCCA). They can choose from three ways to obtain their cannabis: 
a. They can purchase up to 40 grams in licensed pharmacies with or without a 
prescription. The cannabis is produced by a number of commercial state-licensed 
growers;  
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b. They can grow up to six female flowering cannabis plants per household for their own 
consumption, after registering their plants with the IRCCA. The total  annual 
production of the drug must not exceed 480 grams; or 
c. They can join cooperatives to collectively grow cannabis with others. These “cannabis 
clubs” must be registered with the IRCCA and other authorities, and must have 
between 15 and 45 members. (R Walsh J and Ramsey G, s.a) 
Medical use 
Cannabis is cultivated in a number of countries for the production of medicines. In the 
United Kingdom, it is produced for the production of Sativex
®
, although medical use of the 
herb as such is not allowed in this country.(See Section 12) 
 
In many other countries the medical use is permitted as described in Section 9   
 
 “Cannabis flos” is on the market as a pharmaceutical starting material in the 
Netherlands. Starting materials do not need a marketing authorization, but can be legally used 
for compounding in pharmacies, or dispensed as such, which is more often the case for herbs, 
but also for some chemicals e.g. magnesium sulphate crystals as a laxative. Most cannabis is 
dispensed just as the dried herb, but at least one pharmacy prepares oily drops for oral 
administration. 
 
The Dutch company Bedrocan BV produces for the Dutch Ministry of Health, Welfare 
and Sport, but also holds a branch in Canada. The Dutch branch has GMP status. It produces 
six standardized varieties:  
 Sativa types:  
 Bedrocan® (THC: 22 %, CBD: <1 %), 
 Bedrobinol® (THC: 13,5 %, CBD: <1 %) and  
 Bediol® (THC: 6.5 %, CBD: 8 %);   
 Indica types:  
 Bedica® (THC: 14 %, CBD: <1 % and presence of terpenes, e.g. myrcene) and 
 Bedropuur® (THC: 20 – 23 % , CBD: <1 %, only available in Canada and for 
research purposes); 
 A non-psychoactive strain: Bedrolite® (approximately 9 % CBD and 0.4 % THC). 
 
A placebo variety by Bedrocan BV is also available. 
 
Bediol
®
 and Bedica
®
 are marketed in granulated form (i.e. chopped, max. particle size 
5 mm). The cannabis is pharmacy only and prescription only. (Bedrocan, website ) Usually it 
is administered as a herbal tea or by inhalation after vaporization. (Ministry of Health, 
Welfare and Sport, Information  video)  The Dutch Office of Medicinal Cannabis is willing to 
deliver also outside the Netherlands if the authorities of that particular country agree to that. 
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In Canada, 35 producers have been licenced (as per September 2016). (Health Canada, 
website) All licensed producers are subject to inspections by Health Canada to verify 
compliance with the requirements of Marihuana for Medical Purposes Regulations Controlled 
Drugs, the Controlled Drugs and Substances Act (CDSA) and its regulations, as well as the 
Food and Drugs Act (FDA) and its regulations. This also includes meeting the requirements 
of Good Production Practices (GPP), which include standards for microbiological and 
chemical contamination, testing for tetrahydrocannabinol and cannabidiol contents, which 
pest control products are permitted, and maximum residues of such products. (Health Canada, 
2013)  Importation and exportation is possible. 
 
Other countries permitting or considering to permit medical use of cannabis include 
Australia, Brazil, Colombia, Croatia, the Czech Republic, Denmark, Italy, Jamaica, 
Macedonia and Poland. 
15. Illicit production and traffic, and related information 
The World Drug Report 2016 provides detailed information about the production and 
traffic of cannabis herb and resin world-wide.  
 
Cannabis plant cultivation was reported on the territory of 129 countries over the 
period 2009-2014. Given the absence of systematic measurements, however, the extent and 
trends in cannabis cultivation and production are difficult to assess. Most indirect indicators 
come from law enforcement authorities and, to a certain extent, reflect their priorities and 
activities and not simply the existence of cannabis cultivation and production.  
 
Since 1998, the total area of eradicated cannabis plants has decreased, as have seizures 
of cannabis plants. These trends contrast with seizures of cannabis herb and cannabis resin, 
which, after a twofold increase over the period 1998-2004, have remained largely stable. 
 
Reports from Member States on source countries for cannabis resin during the period 
2009-2014 suggest that the world’s largest producer of cannabis resin continues to be 
Morocco, followed by Afghanistan and, to a lesser extent, Lebanon, India and Pakistan. Most 
of the world’s production of cannabis herb takes place in North America, mainly Mexico and 
the United States, for consumption in the sub region, while hydroponic cultivation of cannabis 
plants seems to be concentrated in Canada and the United States. 
 
Reports by Member States over the period  2009-2014 indicate that Albania, 
Colombia, Jamaica, the Netherlands and Paraguay are important source countries of the 
cannabis herb sold in international markets. 
 
In 2014, the Americas accounted for about three quarters of all the cannabis herb 
seized worldwide (North America: 37 % of global seizures; South America: 24 %; the 
Caribbean: 13 %), Africa accounted for 14 % and Europe accounted for 6 %.  
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Despite an increase in cannabis use, the quantity of cannabis herb intercepted in North 
America, after reaching a peak in 2010, has been declining, reflecting the fact that a decrease 
in cannabis production has been reported in Mexico and that cannabis interdiction may have 
become less of a priority in the United States since the decriminalization and legalization of 
recreational use of cannabis in some of the states in that country. Nonetheless, the quantity of 
cannabis herb seized in other parts of the world, particularly in South America, the Caribbean 
and Africa, is actually on the increase 
.  
The sub region in which the largest amount of cannabis resin was seized in 2014 was 
again Western and Central Europe, accounting for 40 % of the global seizures of cannabis 
resin; 32 % of the world total was accounted for by countries in North Africa (mainly 
Morocco and Algeria) and 25 % was accounted for by countries in the Near and Middle East 
(mainly Pakistan, followed by the Islamic Republic of Iran and Afghanistan). (United Nations 
Office on Drugs and Crime, 2016) 
 
The EMCDDA report on cannabis describes how cultivation and traffic over decades 
changed from a rather individual and small scale undertaking in the 1960s to a highly 
professional and large scale operation with the involvement of  organized crime. Moreover, 
cocaine importation now benefits from the infrastructure for cannabis importations 
 
In Europe, the resin has been replaced by the herb that is produced in Europe itself or 
imported, with a great variety in types of herbal cannabis and both indoor and outdoor 
cultivation. (European Monitoring Centre for Drugs and Drug Addiction, 2012a) 
16. Current international controls and their impact 
Scheduling 
Cannabis is scheduled in the Single Convention on Narcotic Drugs in both Schedule I 
and IV. This combination is the strictest control possible under the Conventions. 
Additional controls specific for cannabis and cannabis resin 
In addition to the control measures required because of the scheduling in Schedules I 
and IV, the Single Convention contains controls in the provisions of Article 28, paragraph 1. 
Like for the other two crops regulated in the convention in this way (the poppy plant and the 
coca plant), there is a system of state controls in case a country allows the cultivation of the 
plant. The controls include that a government agency is established designating the area 
where cannabis can be cultivated, licensing the cultivators and purchasing and collecting the 
crops within four months after the harvest. This agency also will have the exclusive right of 
importing, exporting, wholesale trading and maintaining stocks. Article 28 prescribes these 
provisions by referring to Article 23, where similar controls for the cultivation of the poppy 
plant are provided. The controls of cannabis  cultivation should be analogous to the controls 
of the cultivation of the poppy plant, which are described in detail. 
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Article 28, paragraph 2 points out that “[t]his Convention shall not apply to the 
cultivation of the cannabis plant exclusively for industrial purposes (fibre and seed) or 
horticultural purposes.” Horticultural purposes are e.g. the use as wind screens in horticulture. 
 
Article 28, paragraph 3 requires that countries “adopt such measures as may be 
necessary to prevent the misuse of, and illicit traffic in, the leaves of the cannabis plant.” 
 
Although the title of Article 3 of the Convention is “Changes in the Scope of Control”, 
the  text of this article relates only to changing the scheduling. As Article 28 is part of the text 
body of the convention, and not a consequence of the scheduling, the World Health 
Organization mandate to make recommendations on the controls from Article 28 is only 
implicit. 
Consequences of the horticultural and industrial exemption 
The exemption for horticultural and industrial purposes is defined in the Convention in 
terms of how the cultivated plants will be used, and not by their content of the active 
constituent. This provides a way out for illicit cultivation by pretending that the purpose is 
horticultural or industrial. For this reason some countries use instead an upper limit of 
tetrahydrocannabinol (e.g. in the EU, approved cannabis varieties with a content no higher 
than 0.9 % tetrahydrocannabinol) As this example clearly illustrates, limiting the 
tetrahydrocannabinol content instead of defining the purpose of the cultivation can result in 
more effective control and more legal certainty for the grower of cannabis plants.  
 
It would therefore make sense for the Committee to consider recommending an 
exemption by tetrahydrocannabinol content instead of the current exemption based on the 
purpose the product is intended for. Such a recommendation would be to designate certain 
hemp varieties with a known average tetrahydrocannabinol content not higher than a certain  
percentage under which no significant psychoactive effects of the hemp is to be expected.  
 
However, such a change in the scope of control will require amendment of the text 
body of the Single Convention, something that may be much harder to achieve than 
amendment of the schedules. 
The impact of current international controls 
Today, many countries face problems from the strict enforcement of the prohibition as 
prescribed by the Conventions: 
 
The main ones are:  
 friction with other international treaties, such as infringement of religious and 
indigenous rights;  
 many countries have high imprisonment rates for small drug offences, including 
the possession of cannabis for own consumption and those who have once been 
imprisoned have considerable problems to take up their lives after their release; 
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 human right violations occur as collateral damage, e.g. when wells for drinking 
water for the population or for cattle nearby illegal crops are poisoned from 
spraying herbicides; etcetera.  
 The regulations controlling cannabis as Schedule 1 severely hamper research into 
both medical and scientific questions. (Nutt DJ, King LA and Nichols DE, 2013)  
 
In some countries specific population groups suffer heavily under the prohibition, 
whilst other groups a relatively left alone by the authorities. Currently, in the Philippines, 
drug control has given rise to extrajudicial killings after a call by the newly elected president 
Rodrigo Duterte on the police and the population, who announced that he will have 3 million 
people killed..  
 
In recent years, the world has seen the rise of synthetic cannabinoids largely in an 
attempt to get around the legal restrictions on herbal cannabis products. Most of these are 
untested and many are much more potent than the plant products.  
 
In its thirty-sixth meeting, the Committee reviewed six new synthetic cannabinoids 
and recommended the scheduling of two of them, (World Health Organization, 2015)  The 
Critical Review Reports of JWH-018 and AM-2201, which were then recommended for 
scheduling, reported deaths attributed to the use of these substances. (World Health 
Organization, 2014a; World Health Organization, 2014b). On the agenda of the 38th meeting 
of the Committee are again four synthetic cannabinoids listed for Critical Review. 
 
The prevalence of synthetic cannabinoids use is difficult to estimate at a global level 
as data from drug use surveys is only available for some countries. In 2013 and 2014, 
synthetic cannabinoids were the largest group of new psychoactive substances (NPS) 
reported. Newly introduced synthetic cannabinoids are usually not (yet) prohibited and by 
trafficking new synthetic cannabinoids instead of cannabis, drug traffickers evade the 
prohibition of cannabis. Their marketing as ‘herbal products’ that produce experiences similar 
to cannabis seems to have increased their popularity as “legal cannabis substitutes”, however, 
they are perceived, in many cases correctly, as more dangerous. (United Nations Office on 
Drugs and Crime, 2016; United Nations Office on Drugs and Crime, 2015b)   
 
Apparently in a partially illicit and partially licit market, there is a relationship 
between cannabis and synthetic cannabinoids. Therefore, it may be assumed that international 
controls on cannabis and cannabis resin have an impact on the availability of synthetic 
cannabinoids.  However, according to UNODC, it was (2015) too early to assess this impact 
of synthetic cannabinoids on the cannabis market.( United Nations Office on Drugs and 
Crime, 2015b) 
 
Another problem resulting from  the prohibition of cannabis for medical use 
(scheduling in Schedule IV) is the difficulty in organizing clinical trials. Often the authorities 
do not issue the licences needed for this, based on the fact that the treaty implementation at 
the national level does not allow such trials. In the case of multi-centre randomized clinical 
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trials this is even more difficult. In this way the scheduling in Schedule IV has for a long time 
been both cause and effect: the scheduling was an impediment for clinical trials and the 
limited evidence was a reason for maintaining prohibition on clinical trials. (Personal 
experience of several of the authors throughout their careers) In spite of this, scientists in 
some countries were able over time to build considerable evidence for the clinical efficacy as 
described elsewhere in this report. However, in most cases it has been difficult or impossible 
to conduct such trials with standardized and reproducible cannabis batches. 
17. Current and past national controls 
Non-medical use 
For many decades, the control of cannabis was in most or all countries in line with the 
Single Convention (see Section 18, Current international controls and their impact). However, 
the impact of controls has led to a situation where more and more countries regulate cannabis 
in a flexible way and even, in some cases, lift the prohibition of use and trade in order to 
reduce the problems resulting from prohibition. 
 
Non-medical use is or will be soon legal in Uruguay and four states of the United 
States. 
 
In Washington and Colorado, legally taxed and regulated cannabis markets were 
adopted in voter ballots in 2012, followed by similar initiatives in Alaska and Oregon in 2014. 
Washington DC legalized the possession and home cultivation of cannabis. Recent reports on 
cannabis use among adolescents in these two states do not show an increase. (Colaneri N et 
al., 2016; Healthy Kids Colorado Survey, 2015)   
 
Uruguay regulated the cannabis market legally in 2013, granting the government 
control over the import, export, cultivation, production, and sale of cannabis through the 
newly established Institute for the Regulation and Control of Cannabis (Instituto de 
Regulación y Control del Cannabis, IRCCA). (United Nations Office on Drugs and Crime, 
2016)  
 
Canada’s 2015 elected government announced that it will introduce legislation to 
legalize and regulate cannabis for non-medical, non-scientific use in Spring 2017. 
(Anonymous, 2016)  
 
Uruguay has argued that its policy is fully in line with the original objectives that the 
drug control treaties emphasized, but have subsequently failed to achieve - namely, the 
protection of the health and welfare of humankind. Uruguayan authorities have specifically 
argued that the creation of a regulated market for adult use of cannabis is driven by health and  
security imperatives and is therefore an issue of human rights. However, the INCB has made 
clear statements that both Uruguayan and U.S. cannabis regulation models are not in 
compliance with the treaties.(Anonymous, 2016 )   
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A large number of countries have not lifted the prohibition itself, but found other ways 
to mitigate the negative impact of the implementation of the controls required for cannabis. 
Since the early 1970s, some countries adapted the regimen to their needs, e.g. by 
decriminalizing, condoning or legalizing the possession of cannabis and sometimes also the 
distribution and production.  
 
In the Netherlands, the 1976 revision of the Opium Act introduced the distinction 
between “hard” and “soft” drugs, the former having unacceptable risks, the latter not carrying 
such risks. Cannabis and cannabis resin were classified as soft drugs. Simultaneously, the 
possession of 5 gram of cannabis or less was condoned, as well as (under certain conditions) 
the sales of such amounts by “coffee shops”. However, the supply to these coffee shops 
continues to be prohibited and constitutes a continuous friction in the country’s drug policies. 
More recently, some courts refused to convict those involved in the supply of cannabis to 
coffee shops, reasoning that the policy of condoning sales implies that there is a condoned 
supply as well. 
 
In Denmark, possession of less than 10 gram was not prosecuted from 1969 until 
2004, with the turning of “a blind eye” to small-scale sales. In 2004 after the possession was 
“re-criminalized”, street dealing emerged all over Copenhagen and the market-related 
violence of criminal gangs disputing control over selling points increased, including fatal 
shootings. In the five-year period after the crackdown there were more homicides and 
attempted homicides in Denmark than in any five-year period in the previous 20 years. 
(Blickman T, 2014) 
 
In Portugal under a law from 2001, possession and purchase of illicit drugs for 
personal use is an administrative offence and people found to possess drugs, including 
cannabis, are sent to a Drug Addiction Dissuasion Commission of the Ministry of Health. 
(Informal Drug Policy Dialogue, 2011)  
 
Other countries tend to adopt the “Cannabis Social Club” model. This is a model of 
collectively growing cannabis for personal use. Although these clubs are not formally legal in 
any country at the moment, they are condoned in Spain. In some European cities they have 
the support of local authorities. (Blickman T, Personal information) 
Regulations for medical use 
A listing of countries with licit production for medical purposes has been provided in 
Section 10 (Therapeutic applications and extent of therapeutic use). In most of these countries 
and states, no specific provisions are established to meet the requirement of Article 28 of the 
Single Convention that a state agency takes in the harvest and controls the distribution of the 
production.  
 
The Netherlands established the Office of Medicinal Cannabis within the Ministry of 
Health, Welfare and Sport in 2001 to meet the requirement by law that the Minister makes 
sufficiently medical cannabis available for scientific and medical purposes. 
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The office is responsible for all the functions mentioned in the Convention. All actors 
in the production and distribution chain (except pharmacies) require a license and are 
contracted by the OMC. The medical cannabis is distributed as the inflorescences (“Cannabis 
flos”) by a distributor company on behalf of the OMC. It can be dispensed to patients with a 
prescription. As Cannabis flos is on the market as a starting material, it can also be used by 
pharmacies for compounding preparations and at least one pharmacy uses it to make oily 
drops, which allows for more easy dosing by the patient. 
 
In the United States, the National Institute on Drug Abuse (NIDA) is the national 
agency according to Article 28. However, it is only the production for scientific purposes that 
is controlled by NIDA; it does not interfere with the production in the states that legalized 
cannabis. In those states that allow medical use of cannabis, local regulations are 
implemented that regulate who can have access and how. 
 
In Canada, the Access to Cannabis for Medical Purposes Regulations provide a 
framework for commercial production by licensed producers responsible for the production 
and distribution of quality-controlled fresh or dried marijuana or cannabis oil or starting 
materials (i.e., marijuana seeds and plants) in secure and sanitary conditions. These 
regulations also include provisions for individuals to produce a limited amount of cannabis 
for their own medical purposes or to designate someone to produce it for them. Individuals 
with a medical need, and who have the authorization of their health care practitioner, can 
access cannabis in three ways: they can register with licensed producers, they can register 
with the Ministry of Health to produce a limited amount for their own medical purposes, or 
they can designate someone else to produce it for them. (Health Canada, 2016) 
 
A few more countries recently decided to allow medical use, including Jamaica and 
Colombia, and this list is still growing. 
18. Other medical and scientific matters relevant for a 
recommendation on the scheduling of the substance 
Contamination hazards and quality control
3
  
Where there is no government control over the cultivated medicinal cannabis, 
producers do not necessarily apply basic Good Production Practices like GAP, GMP, GLcP 
and GDP practices.  This has consequences for the safety and efficacy of the medicinal 
cannabis: 
 there can be considerable batch-to-batch variation in strength and the qualitative 
composition of the medicine, resulting in varying effectiveness. 
 cannabis is known for containing Aspergillus fumigatus L., a fungus that can infect the 
user and produces toxins that may provoke a psychosis. A Dutch study compared 
                                               
3 The following part of this section is based on a document prepared by the author for the 36th Meeting 
of the Expert Committee on Drug Dependence. 
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illegal cannabis batches with medicinal cannabis produced under state control. Some 
samples of the former contained up to 480,000 colony forming units (CFU)/gram, 
while the  latter was microbiologically safe (total aerobic microbial count of <10 
CFU/g, total yeast and mould count of <10 CFU/g, and absence of Pseudomonas 
aeruginosa, Staphylococcus aureus, and bile-tolerant gram-negative bacteria). 
(Hazekamp A et al., 2005)  
 contamination can also derive from pesticides used during production or from heavy 
metals in the substrate (e.g. from rock wool). 
An example of production with good quality assurance is the Dutch medicinal 
cannabis. This is produced under responsibility of the Ministry of Health and meets a number 
of quality requirements: consistent strength of tetrahydrocannabinol and cannabidiol, 
consistent composition of secondary cannabinoids, absence of microbiological contamination, 
pesticides and heavy metals, and humidity. Where there is a norm provided in the European 
Pharmacopoeia, this norm is followed. (Office for Medicinal Cannabis, s.a)   
 
More and more countries opt today for decriminalized, condoned or legalized 
production and distribution systems. However, in such systems, it is often the case that 
production/growing  remains illegal and prone to prosecution. As a consequence, quality 
assurance for non-medical use of cannabis is not possible. Also in some countries where 
medical use of cannabis is permitted, production is often left in the hands of amateurs or other 
producers with no knowledge of requirements for pharmaceutical products.  
 
It would be logical if quality assurance for commercialized non-medically used 
cannabis should be of equal level as that for food, e.g. by the usual quality assurance under 
HACCP (Hazard Analysis and Critical Control Points). Production would also be subject to 
similar surveillance by the authorities as food production. 
 
For medical cannabis, quality standards should be higher than for recreational 
cannabis, because medical use requires a fixed dose-effect relation and patients need to be 
able to dose at a level below the psychoactive threshold. Also many patients are more 
vulnerable than the average person and some of them are immunocompromised, thus 
requiring microbiologically safe cannabis. Therefore, well defined products and full 
pharmaceutical quality control including GAP, GMP, GLcP and GDP practices is necessary 
with oversight by the health authorities. 
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Conclusions 
Despite that the scheduling system of substances under the Single Convention on 
Narcotic Drugs is supposed to be based on scientific assessments, the WHO has never 
reviewed cannabis and cannabis resin.  This means also that the Expert Committee continues 
to recommend that cannabis is not to be used medically despite growing evidence of 
considerable medical use world-wide, including the availability of a pharmaceutical 
preparation with a marketing authorization in multiple countries. Many countries are 
struggling with the impact of the prohibition of cannabis with its wide negative impact on 
societies (including through human rights violations) and on drug markets and drug use, 
including on the market of synthetic cannabinoids. 
 
Committee recommendations are needed on the following topics: 
 
1. Whether a Critical Review should be conducted for reviewing the current 
scheduling in Schedules I and IV. Each of the following reasons would justify a 
recommendation for a Critical Review: 
a. because WHO has never conducted a Critical Review, meaning that there is no 
scientific justification for the current scheduling; 
b. because the wide-spread medical use, including the use of preparations with a 
marketing authorization is in contradiction to listing in Schedule IV; 
c. because it is not clear whether the dependence-producing properties of 
cannabis and cannabis resin are between codeine and morphine (justification 
for Schedule I) or between dextropropoxyphene  and codeine (justification for 
Schedule II) or below those of dextropropoxyphene (justification for not 
scheduling). 
 
2. On the medical use of cannabis and its preparations (which can include revoking 
old recommendations by the Committee) 
 
3. On the need of quality control on cannabis and cannabis products for medical and 
non-medical use. 
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About this report 
 
The World Health Organization’s (WHO) Expert Committee on 
Drug Dependence will convene again in November 2016.  In spite 
that the Expert Committee has decided several times to conduct a 
review of cannabis in “a future meeting”, the WHO Secretariat has 
not been able to prepare the “Pre-review Report”, which is an 
essential requirement for a proper discussion by the ECDD. 
DrugScience specially prepared the Pre-review Report “Cannabis 
and Cannabis Resin” for the Expert Committee’s use.  This will enable 
the WHO Expert Committee on Drug Dependence (ECDD) to conduct 
its first-ever review of the drug.  This will rectify the fact that a 
scientific review of the status of cannabis in the international drug 
treaties has not been conducted since 1935.  If the ECDD conducts a 
review in its November 2016 meeting, the world-wide prohibition of 
cannabis can be discussed in the UN’s Commission on Narcotic Drugs 
in March 2018. 
DrugScience has requested the WHO to circulate the 
DrugScience Preview Report in good time among the participants of 
the 38th Meeting of the ECDD and moreover, also requested that the 
agenda item of Pre-review of Cannabis and Cannabis Resin be placed 
on the ECDD Agenda. 
 
 
ISBN  978-1-5272-0260-3 
